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 1.  INTRODUCTION  
         Oral route of drug administration is oldest and safest mode of drug 
administration. It posses several advantages. It does not possess the sterility problem 
and minimal risk of damage at the site of administration. It provides accurate dosing 
without assistantship of administration. In conventional oral drug delivery system, 
there  is  little  or  no  control  over  release  of  drug,  and  effective  concentration  at  the  
target site can be achieved by administration of grossly excessive dosage form. This 
kind of dosing pattern result in constantly changing, unpredictable and often sub or 
supra therapeutic plasma concentration, leading to marked side effects in some cases. 
Moreover, the rate and extent of absorption from conventional formulation may  vary 
greatly, depending on factor such as physiochemical properties of drug, presence of 
excipients, various physiological factors such as presence or absence of food, pH of 
gastrointestinal tract, G.I. motility etc.   
         The above problem can be minimized by oral controlled drug delivery. In oral 
controlled drug delivery the amount of drug release is constantly predetermined and 
these constant releases of drug provide a constant blood plasma level of drug for a 
therapeutic response. The oral controlled drug delivery have many advantage to 
conventional delivery- it decrease the fluctuation of drug plasma concentration, it 
reduce toxicity, provide a sustained effects, reduced the dosing frequency. Apart from 
other advantage it reduces total amount of drug used, improve patient compliance and 
reduced patient care time. 
                  The disadvantage of oral controlled release product are longer time to 
achieve therapeutic blood concentration, possible increase variation in bioavailability 
after oral administration, enhanced first pass effect, dose dumping, sustained 
concentration in oral dose case, lack of doses flexibility and usually grater expense. 
                   Hydrophilic polymers are widely used in oral controlled drug delivery 
due to their flexibility to produce desirable drug release profile, cost effectiveness, 
and broad regulatory acceptance. Among the hydrophilic polymers, HPMC 
(hydroxyproylmethylcellulose) is the most widely used carrier for the preparation of 
oral controlled drug delivery system due to its properties such as its ability to swell 
upon  jellification  once  contact  with  water,  and  its  very  low  toxicity  and  easy  of  
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manufacture, the gel becomes a viscous layer acting as a protective barrier to both 
influx of water and efflux of drug in the solution. On the other hand, hydrophobic 
polymer, such as EC can be alternative to the swelling polymers by forming an inert 
matrix with no physiological action and stable at different pH values and moisture 
levels when a tablet with hydrophobic matrix is placed in the dissolution medium, the 
drug at surface is released quickly, with a possible burst effects, requiring its 
replacement drug from inner layers that must diffuse through the pores until it reaches 
the surface. 
         Physician can achieve several desirable therapeutics advantages by prescribing 
sustained release dosage form. Since, the frequency of drug administration is reduced, 
patient’s compliances can be improved and the drug administration can be made more 
convenient as well. The blood level oscillation characteristics of multiple dosing form 
of conventional dosage form is reduced, because more even blood level is maintained 
in the design of sustained release dosage form. The total amount of drug 
administered, thus maximum availability with a minimum dose. In addition, the safety 
margin of high potency drug can be increased and the incidence of both local and 
systemic adverse effects can be reduced in sensitive patients. Overall, increased 
administration of sustained release dosage form gives increased reliability. 
        Sustained release technology is relatively new field and as a consequence, 
research in the field has been extremely fertile and has produced many discoveries. 
With  many  drugs,  the  basic  goal  is  to  achieve  a  steady  state  blood  level  that  is  
therapeutically effective and non-toxic for an extended period of time. 
The design of proper dosage form is an important element to accomplish this 
goal. Sustained release, sustained action, prolonged action, controlled release, 
extended action, timed release and depot dosage form are term used to identify drug 
delivery system that are designed to achieve prolonged therapeutic effect by 
continuously releasing medication over an extended period of time after 
administration of a single dose. In the case of oral sustained released dosage form, an 
effect is for several hours depending upon residence time of formulation in the GIT. 
 Not all the drugs are the suitable candidates for the sustained release dosage 
form. Ideal characteristic of the drug for the sustained release dosage form are; 
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v Drug should have a shorter half-life as drug with a longer half-life are 
inherently long acting drugs. 
v Drug should be absorbed from large portion of gastrointestinal tract, since 
absorption must occur through the gut. 
v Drug should be having a good solubility profile to be a good candidate for 
sustained release dosage form. 
v Dose of the drug should not be too large, as a larger dose is to be incorporated 
into sustained release dosage form. 
1.1 POTENTIAL ADVANTAGE OF SUSTAINED RELEASE DOSAGE 
FORM:  
1) Avoid patient’s compliance problem due to reduced frequency of dosing. 
2) Blood level oscillation characteristics of multiple dosing of conventional 
dosage form are reduced because a more even blood level is maintained. 
3) Employ a less total drug. 
4) Minimize or eliminate local or systemic side effects. 
5) Minimize drug accumulation with chronic dosing. 
6) Obtained less potential of reduction in drug activity with chronic use. 
7) Improved efficiency in treatment. 
8) Cure or control condition more promptly. 
9) Improved control of condition i.e. reduced fluctuation in drug level. 
10)  Improved bioavailability of some drugs. 
11)  Make a use of special effects, e.g. sustained release aspect for relief of     
       arthritis by dosing before bedtime. 
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12)  Economy. 
13) Overall, administrations of sustained release form enable increased reliability 
of therapy. 
.1.2 MATRIX SYSTEM:  
  The matrix system is most often used for a drug-controlled release from a 
pharmaceutical dosage form. Among the innumerable method used in controlled 
release drug from pharmaceutical dosage form, the matrix system is the most 
frequently applied; it is release system for delay and control of the release of the drug 
that is dissolved or dispersed in a resistant supports to disintegration. 
To define matrix, it is necessary to know the characters that differentiate it 
from other controlled release dosage forms. Hence the following must be considered: 
v The chemical nature of support (generally, the support are formed by 
polymeric net) 
v The physical state of drug (dispersed under molecular or particulate form or 
both). 
v The matrix shape and alteration in volume as a function of time. 
v The route of administration (oral administration remains the most widely used 
but other routes are adaptable). 
v The release kinetic model.            
1.3 THE CLASSIFICATION OF MATRIX SYSTEM: 
 
       Mineral matrix: 
        Drug retained in the support. 
        Drug adsorbed on the support 
 
        Lipidic matrix: 
        Delivery by diffusion. 
        Delivery by surface erosion 
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       Hydrophillic matrix: 
       Unlimited swelling, delivery by diffusion. 
       Limited swelling controlled delivery through swelling 
 
       Inert matrix: 
       Controlled delivery by diffusion 
       Biodegradable matrix: 
       Non-Lipidic. 
 
1.4 ADVANTAGES OF MATRIX SYSTEM 
      The interest awakened by matrix system in last few years is completely 
justified in view of the major advantages. Among these, the following stand out. With 
proper control of manufacturing process, reproducible release profiles are possible. 
There is no risk of “dumping” of a large part of dose, through the structure 
makes the immediate release of a small amount of active principle unavoidable. 
Their capacity to incorporate active principle is large, which suits them to 
delivery of large dosage           
1.5 PRINCIPAL OF MODIFIED DRUG RELEASE:  
Following either of the two principles can modify drug release. 
1.5.1 Barrier principal  
        In this method the retardant material is imposed between the drug and elusion 
medium. Drug release is by diffusion of the drug through the barrier and /or erosion 
of the barrier or permeation of the barrier by moisture 
                                                                                 . 
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Figure no.1. 
Barrier mediated models of sustained release dosage form regimen. 
 
 A. Drug diffusion through the barrier, 
 B. permeation of barrier by elution media followed by drug dissolution, 
 C. Erosion of barrier releasing drug, 
 D. rupture of permeation of elutiomedia. 
 
1.5.2 Embedded matrix: 
        In this drug is dispersed/embedded in a matrix of retardant material that may be 
encapsulated in a particulate form or compressed into the tablet. Drug release occurs 
by permeation of water leaching extraction of diffusion of drug from the matrix and 
erosion of matrix material.     
 
Figure No. 2  
Embedded matrix concept as a mechanism of controlled released in sustained 
release 
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A. Dosage form design network model a drug is insoluble in the retardant material.  
B.  Drug is soluble in the retardant material. Diffusion profile etc. Characterize drug 
release from matrix system.  
1.6 SWELLABLE MATRIXS AS SYSTEM FOR ORAL DELIVERY: 
Monolithic devices or matrices represent a substantial part of drug delivery 
systems. Matrices containing swellable polymers are referred to as   
Hydrogel matrices 
Swellable control release systems. 
Hydrophillic matrix tablet  
Swellable matrices for oral administration are commonly manufactured as 
tablet by compression of hydrophilic microparticulate polymers. Therefore, the most 
appropriate classification for these systems is swellable matrix tablet. They are 
constituted of a blend of drug and one or more hydrophilic polymers.  
The release of drug from swellable matrix tablet is based on glassy-rubbery 
transition of polymer as a result of water penetration into the matrix. The interaction 
between water, polymer and drug are the primary factors for drug release. However, 
various formulation variables such as polymer grade, drug–polymer ratio, drug 
solubility and drug and polymer particle size, can influence drug release rate to 
greater or lesser degree.  
The central element of the mechanism of drug release in the gel layer (rubbery 
polymer), which is formed around the matrix. The gel layer is capable of preventing 
matrix disintegration and further rapid water penetration.Water penetration, polymer 
swelling, drug dissolution and diffusion and matrix erosion are phenomenon 
determining gel layer thickness. Finally drug release is controlled by drug diffusion 
through the gel layer and/or by erosion of the gel layer.  
1.7. MECHANISMS OF DRUG RELEASE FROM MATRIX SYSTEM  
        The release of drug from controlled devices is via dissolution of the matrix or 
diffusion of drug through the matrix or a combination of the two mechanisms. 
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1.7.1. Dissolution controlled systems 
        A drug with slow dissolution rate will demonstrate sustaining properties, since 
the release of the drug will be limited by the rate of dissolution. In principle, it would 
seem possible to prepare extended release products by decreasing the dissolution rate 
of drugs that are highly water-soluble. This can be done by: 
Preparing an appropriate salt or derivative 
        Coating the drug with a slowly dissolving material – encapsulation dissolution 
control incorporating the drug into a tablet with a slowly dissolving carrier – matrix 
dissolution control (a major disadvantage is that the drug release rate continuously 
decreases with time). 
        The dissolution process can be considered diffusion-layer-controlled, where the 
rate of diffusion from the solid surface to the bulk solution through an unstirred liquid 
tablet is the rate-determining step. The dissolution process at steady-state is described 
by the Noyes-Whitney equation: 
Dc/dt = kDA(Cs-C) = D/hA(Cs-C) 
 
        dC -  dissolution rate 
        kd  -  the dissolution rate constant (equivalent to the diffusion     
coefficient Divided by the thickness of the diffusion layer D/h) 
         D  - Diffusion coefficient 
        Cs  -  saturation solubility of the solid 
         C  -  Concentration of solute in the bulk solution 
 
        Equation 1 predicts that the rate of release can be constant only if the following 
parameters are held constant: surface area, diffusion coefficient and diffusion layer 
thickness and concentration difference. However, under normal conditions, it is 
unlikely that these parameters will remain constant, especially surface area, and this is 
the case for combination diffusion and dissolution systems. 
1.7.2. Diffusion controlled systems 
Diffusion systems are characterized by the release rate of a drug being 
dependent on its diffusion through an inert membrane barrier, which is usually a 
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water-insoluble polymer. In general, two types or subclasses of diffusion systems are 
recognized: reservoir devices and matrix devices.  
1.7.2.1. Reservoir devices 
In these formulations where tablet coating constitutes the main factor in 
controlling drug release. Examples of materials used to control drug release include 
hardened gelatin, methyl or ethyl cellulose, polyhydroxymethacrylate, methacrylate 
ester copolymers, and various waxes. Ethyl cellulose and methacrylate ester 
copolymers are the most commonly used systems in the pharmaceutical industry. 
 
 
 
 
 
Figure3. Schematic representation of a matrix release system 
 
1.7.3 Bioerodible and combination diffusion and dissolution system 
        Bioerodible devices constitute a group of system for which mathematical 
description of release kinetics can be quite complex. Bioerodible matrix system 
consists of the drug dispersed in an erodible matrix.  
 
                                                            
  
           
                    Drug dispersed in matrix  
                                  Time = 0 
 
 
   
                  Drug dispersed in matrix  
                                  Time = t 
 
Figure 4: Representation of a Bioerodible matrix system. 
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        Drug dispersed in the matrix before release at time = 0. At time = t release by 
drug diffusion or matrix erosion has occurred. 
The mechanism of release from simple erodible slab, cylinders, and sphere has 
been described .by Eq. A simple expression describing release from all three of these 
erodible devices is  
M1/M = 1- (1-K0t/C0a)n 
 
         Where n=3 for a sphere, n=2 for a cylinder and n=1 for a slab. The radius of a 
sphere, or cylinder, or the half-height of a slab is represented by a. Mt is the mass of a 
drug released at infinite time. As a further complication, these systems can combine 
diffusion and dissolution of both matrix material and the drug. Not only can drug 
diffuse out of the dosage form, but also the matrix itself undergoes a dissolution 
process.  The   complexity  of  the  system can  arise  from the  fact  that,  as  the  polymer  
dissolves, the diffusional path-length for the drug changes. These usually result in a 
moving boundary diffusion system. Zero order release can occur only if surface 
erosion occurs and surface area dose not change with time. The inherent advantage of 
such  a  system  is  that  bioerodible  property  of  the  matrix  dose  not  result  in  a  ghost  
matrix. 
The disadvantages of these matrix systems are that release kinetics is often 
hard to control, since many factors affecting to both the drug and the polymer must be 
considered. Another method for the preparation of bioerodible system is to attach the 
drug directly to the polymer by a chemical bond. Generally, the drug is released from 
the polymer by hydrolysis or enzymatic reaction. This makes control of the rate of 
release somewhat easier. Another advantage of the system is the ability to achieve 
very high drug loading, since the amount of drug placed in the system   is limited only 
by the available sites on the carrier. 
A third type, which in this case utilizes a combination of dissolution and 
diffusion, is that of a swelling controlled matrix. In this the drug is dissolved in the 
polymer, instead of an insoluble or erodible polymer. This allows entrance of water 
which causes dissolution of drug and diffusion out of the swollen matrix.  
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In these systems the release rate is highly dependent on polymer-swelling rate, 
drug solubility, and the amount of soluble fraction in the matrix. This system usually 
minimizes burst effects, since polymer swelling must occur before drug release. 
1.8 ADVANTAGES OF HYDROPHILIC MATRIX TABLET  :  
1) With proper control of the manufacturing process, reproducible release 
profiles are possible. The variability associated with them is slightly less 
than that characterizing coated release form. 
2) Structure allows an immediate release of small amount of active principle 
there is no risk of dose dumping. 
3) Their capacity to incorporate active principle is large, which suits them to 
delivery of large doses.  
4) The manufacturing processes are notably simple. Tablet formulation can 
be done via direct compression or by wet granulation techniques. 
5) Large variety of nonexpensives gelling agents is approved for oral use by   
the Competent official organization. 
6) The safety margin of high-potency drugs can be increased. 
7) The drug release from hydrophilic matrices show a typical time dependent 
profile i.e. decreased drug release with time because of increased diffusion 
path length.  
1.9 FACTORS INFLUENCING THE DRUG RELEASE FROM MATRIX: 
v Choice of matrix material. 
v Amount of drug incorporated in the matrix. 
v Viscosity of the hydrophilic material in aqueous system at a fixed   
v Concentration.  
v Drug: matrix ratio. 
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v Tablet hardness, porosity, and density variation. 
v Entrapped air in tablet. 
v Tablet shape and size. 
v Drug particle size. 
v Solubility of drug in aqueous phase. 
v Surfactants and other additives. 
1.10 TABLET MANUFACTURING METHODS :  
Tablets are manufactured by wet granulation, Dry granulation or direct 
compression method. 
1] Wet Granulation 
  Wet  granulation  is  the  process  in  which  a  liquid  is  added  to  a  powder  in  a  
vessel equipped with any type of agitation that will produce agglomeration or 
granules. These granules after drying are compressed to form tablet. 
2] Dry Granulation 
In this technique, there is no use of liquids. The process involves the 
formation  of  slugs.  Then  the  slugs  are  screened  or  milled  to  produce  granules.  The  
granules formed are then compressed to form tablet. 
3) Direct compression 
The term direct compression is used to define the process by which tablet is 
compressed directly from powder blends of active ingredient and suitable excipients, 
which will flow uniformly in the die cavity and forms a firm compact. 
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1.11 DRUG PROPERTIES RELEVENT TO CONTROLLED RELEASE 
FORMULATIONS  
The design of controlled - release delivery systems is subject to several 
variables of considerable importance. Among these are the route of drug delivery, the 
type of delivery system, the disease being treated, the patient, the length of therapy 
and  the  properties  of  the  drug.  Each  of  these  variables  are  interrelated  and  this  
imposes  certain  constrains  upon  choices  for  the  route  of  delivery,  the  design  of  the  
delivery system and the length of therapy. Properties of drugs are very important for 
designing a sustained release dosage form mainly physicochemical and biological 
properties of the drug are most important. 
1.11.1 Physicochemical properties: 
 A) Aqueous solubility and pKa:  
A drug to be absorbed it must be dissolved in the aqueous phase surrounding 
the site of administration and then partition into the absorbing membrane. Two of the 
most important physicochemical properties of a drug that influence its absorptive 
behavior  are  its  aqueous  solubility  and  if  it  is  a  weak  acid  or  base  its  pKa.  These  
properties pay an influential role in the performance of controlled release systems. 
The aqueous solubility of a drug influences its dissolution rate, which in turn 
establishes its concentration solution and hence the driving force for diffusion across 
membrane. 
Dissolution rate is related to aqueous solubility as shown by the Noyes-
Whitney equation that, under sink condition is:- 
dc/dt = KDACS 
        Where, dc/dt  = Dissolution rate 
                        KD = Dissolution rate constant. 
                         A        = Total surface area of the drug particles.  
                         Cs       = Aqueous saturation solubility of the drug. 
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  The  dissolution  rate  is  constant  only  if  surface  area  'A'  remain  constant,  but  
the  important  point  to  note  is  that  the  initial  rate  is  directly  proportional  to  aqueous  
solubility  Cs.  Therefore,  aqueous  solubility  of  a  drug  can  be  used  as  a  first  
approximation of its dissolution rate. Drugs with low aqueous solubility have low 
dissolution rates and usually suffer oral bioavailability problems. 
Aqueous  solubility  of  weak  acids  and  bases  is  governed  by  the  pKa  of  the  
compound and pH of the medium. 
For weak acid, 
St = So (1+ka/[H+]) = So(1+10 pH – pKa)…………...(1) 
        Where,  
        St = Total solubility (both ionized and un-ionized forms) of the weak acid     
          So = Solubility of the un - ionized form 
         Ka = Acid Dissociation constant 
         H+ = hydrogen ion concentration of the medium. .  
 
         Equation (1) predicts that the total solubility, st of a weak acid with a given 
pKa can be affected by the pH of the medium. 
 
For a weak base, 
 
St = So (1+[H+] / Ka = So (1+10 Pka – PH) ……………… (2) 
 
Where, 
        St = Total solubility (both conjugate acid and free base forms) of the weak base. 
        So = Solubility of the free base form 
        Ka= Acid dissociation constant of the conjugate acid.  
      So total  solubility,  St  of a weak base whose conjugate acid has a given pKa, 
which can be affected by the pH of the medium. 
         In general, extremes in the aqueous solubility of a drug are undesirable for 
formulation into controlled release product. A drug with very low solubility and a 
slow dissolution rate will exhibit dissolution limited absorption and yield an 
inherently sustained blood level.  
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Formulation of such a drug into a controlled release system may not provide 
considerable benefits over conventional dosage forms. Any system upon diffusion of 
drug through a polymer as the rate - limiting step in release would be unsuitable for a 
poorly soluble drug, since the driving force for diffusion is the concentration of drug 
in the polymer or solution, and this concentration would be low.  For a drug with very 
high solubility and a rapid dissolution rate, it is often quite difficult to decrease its 
dissolution rate to slow its absorption. Preparing a slightly soluble form of a drug with 
normally high solubility is, however, one possible method for preparing controlled 
release dosage forms. 
B) Partition Coefficient 
Between time that a drug is administered and the time is eliminated from the 
body, it must diffuse through a variety of biological membranes that act primarily as 
lipid like barriers.  
A major criteria in evaluation of the ability of a drug to penetrate these lipid 
membranes is its apparent oil / water partition coefficient defined as 
K = C0/CW 
Where, 
Co  =  Equilibrium  concentration  of  all  forms  of  the  drug  e.g  ionized  and                    
unionized in  an organic phase at equilibrium. 
           Cw =  Equilibrium concentration of all forms in aqueous phase. 
In general, drugs with extremely large values of ‘K’ are very oil soluble and 
will  partition  into  membrane  quite  readily.  According  to  Haunch  correlation,  the  
logarithm of the activity of a drug or its ability to be absorbed and the logarithm of its 
partition coefficient having parabolic relationship. The explanation for this 
relationship is that the activity of a drug is a function of its ability to cross membranes 
and interact with the receptor.  The more effectively a drug crosses membranes, the 
greater its activity. The optimum partition coefficient value of a drug in which it most 
effectively permeates membranes and thus shows the greatest activity.    
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The value of K at which optimum activity is observed is approximately 
1000/1. Drugs with a partition coefficient that is higher or lower than the optimum is, 
in general, poorer candidates for formulation into controlled-release dosage forms. 
C) Drug stability 
One important factor for oral dosage forms is the loss of drug through acid 
hydrolysis and/or metabolism in the GI tract. Since a drug in the solid state undergoes 
degradation a much slower rate than a drug in suspension or solution. It is possible to 
improve significantly the relative bioavailability of a drug that is unstable in the 
stomach; the most appropriate controlling unit would be one that releases its content 
only in the intestine. The reverse in the case for those drugs that are unstable in the 
environment of the intestine, the most appropriate controlling unit in this case would 
be  one  that  releases  its  contents  only  in  the  stomach,  so,  drugs  with  significant  
stability  problems  in  any  particular  area  of  the  GI  tract  are  less  suitable  for  
formulation into controlled release systems that deliver their content uniformity over 
the length of the GI tract. Controlled drug delivery systems may provide benefits for 
highly unstable drugs because the drug may be protected from enzymatic degradation 
by incorporation into a polymeric matrix. 
D) Protein Binding 
There are some drugs which having tendency to bind with plasma proteins 
(e.g. Albumin) and causes retention of the drug in the vascular space. The main force 
of attraction responsible for binding is vanderwal forces, hydrogen bonding and 
electrostatic forces. In general, charged compounds, because of electrostatic effects. 
If a drug binds with protein then the distribution of the drug into the 
extravascular space is governed by the equilibrium process of dissociation of the drug 
from the protein. The drug-protein complex can serve therefore as a reservoir in the 
vascular space for controlled drug release to extravascular tissues, but only for those 
drugs that exhibit a high degree of binding. Thus, the protein binding characteristics 
of a drug can play a significant role in its therapeutic effect, regardless of the type of 
dosage form.  
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Extensive binding to plasma proteins will be evidenced by a long half-life of 
elimination for the  drug and such drugs generally does not required a controlled-
release dosage form, however, drugs that exhibit a high degree of binding to plasma 
protein also might bind to biopolymers in the GI tract, which could have an influence 
on controlled-drug delivery. 
E) Molecular size and diffusivity: 
Drugs in many controlled-release systems must diffuse through a rate 
controlling membranes or matrix. The ability of a drug to diffuse through membranes, 
it's so called diffusivity [diffusion coefficient), is a function of its molecular size (or 
molecular weight). An important influence upon the value of the diffusivity. 'D', in 
polymers is the molecular size for molecular weight) of the diffusing species. For 
most polymers, it is possible to relate logD empirically to some function of molecular 
size as 
Log D = -Sv log V + Kv   = - SM logM + Km 
                     Where, 
   V =  molecular Volume. 
   M  =  molecular weight. 
          SV,Sm,Kv, Km  =  constant 
  
The value of 'D' thus is related to the size and shape of the cavities as well as 
size and shape of drugs. Generally, values of the diffusion coefficient for intermediate 
molecular, weight drugs, i.e.150 to 400, through flexible polymers range from 10-6 to 
10-9 cm2 / sec, with values on the order of 108 being most common. A value of 
approximately 10-6 is typical for these drugs through water as the medium. For drugs 
with a molecular weight greater than 500, the diffusion co-efficient in many polymers 
frequently are so small that they are difficult to quantify, i.e., less than 10-12 cm2/sec. 
Thus, high molecular weight drugs and/or polymeric drugs should be expected to 
display very slow release kinetics in controlled release devices using diffusion 
through polymeric membranes or matrices as the releasing mechanism. 
 
	Department of  Pharmaceutics. AVPC 	Page		18
 
1.11.2. Formulation variables 
The physicochemical characteristics of the drug, in particular its aqueous 
solubility, should be considered in the formulation of a matrix system. Other drug 
properties affecting system design include drug stability in the system and at the site 
of absorption, pH-dependent solubility, particle size and specific surface area. 
Drug particle size 
Effect of drug particle size on release is important in the case of moderately 
soluble drugs. In the case of water-soluble aminophylline or propranolol HPMC-
based tablet an increase in drug particle size did not significantly alter the release rate 
of  the  drug.  A noticeable  effect  was  seen  only  at  a  low drug:  HPMC ratio  and  at  a  
large drug particle size (above 250µm), in this case, rapid dissolution of the water 
soluble drug would leave a matrix with low tortuosity and high porosity.  Another 
study showed that for a given effective surface area, diclofenac particle size 
influenced  the  release  rate  from  HPMC  tablet.  The  smallest  particle  size  of  drug  
dissolved more easily when dissolution medium penetrated through the matrix 
resulting in a greater role for diffusion. The larger particle size dissolved less readily 
and therefore was more prone to erosion at the matrix surface.  
Drug: polymer ratio 
For diclofenac tablet formulated with HPMC, an increase in polymer: drug 
ratio reduced the release rate. This was because an increase in polymer concentration 
caused an increase in the viscosity of the gel (by making it more resistant to drug 
diffusion and erosion) as well as the formation of a gel layer with a longer diffusional 
path. Diffusional release of the water soluble drug metoprolol decreased with 
increasing HPMC incorporation. By varying the polymer level (Methocel® K4M 10-
40%), Nellore et al. (1998) achieved different metoprolol in vitro release profiles.  
Polymer type 
Various grades of commercially available HPMC differ in the relative 
proportion of the hydroxypropyl and methoxyl substitutions; increasing the amount of 
hydrophilic hydroxypropyl groups leads to a faster hydration: Methocel® K 
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>Methocel® E > Methocel® F. Generally rapid hydrating Methocel® K grade is 
preferred, especially for highly soluble drugs where a rapid rate of hydration is 
necessary. It is important to note that an inadequate polymer hydration rate may lead 
to dose dumping, due to quick penetration of gastric fluids into the tablet core (Dow 
Pharmaceutical Excipients, 1996). In each grade, for a fixed polymer level, the 
viscosity of the selected polymer affects the diffusional and mechanical 
characteristics of the matrix. By comparing different Methocel® K viscosity grades, 
the higher viscosity gel layers provided a more tortuous and resistant barrier to 
diffusion, which resulted in slower release of the drug (metoprolol HCl). Sung et al. 
(1996) compared different viscosity grades of HPMC (Methocel® K100LV, K4M, 
K15M, K100M). The fastest release of adinazolam mesilate was achieved for the 
K100LV formulation. The K4M formulation exhibited a slightly greater drug release 
than K15M and K100M. Due to the lack of a significant difference in the release 
profiles between K15M and K100M, the authors suggested a limiting HPMC 
viscosity of 15000cP, above which, if viscosity increased, the release rate would no 
longer decrease. In the case of ethyl cellulose, the findings are completely different. 
The lower viscosity grades of ethyl cellulose are more compressible than the higher 
viscosity grades, resulting in harder tablet and slower release. 
Fillers 
A study the effect of filler (57% of the tablet weight) on a metoprolol 
formulation at 20% Methocel® K4M level. They concluded that filler solubility had a 
limited effect on release rate. The release profiles showed a decrease of about 5-7% 
after 6h, as the filler was changed from lactose to lactose – microcrystalline cellulose 
then to dicalcium phosphate dihydrate -microcrystalline cellulose. Addition of soluble 
fillers enhanced the dissolution of soluble drugs by decreasing the tortuosity of the 
diffusion path of the drug, while insoluble fillers like dicalcium phosphate dihydrate 
got entrapped in the matrix. Also, it was assumed that the presence of swelling 
insoluble filler like microcrystalline cellulose changed the release profile to a small 
extent due to a change in swelling at the tablet surface. Changing the filler from 100% 
dicalcium phosphate dihydrate to 100% lactose resulted in an increase in metoprolol 
release from Methocel® K100LV tablet at 4, 6 and 12h this was explained by 
dissolution of lactose and the consequent reduction in the tortuosity and or gel 
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strength of the polymer. Similar dissolution profiles were obtained for filler 
concentration up to 48%. No dose dumping due to stress cracks (Dow Pharmaceutical 
Excipients, 1996) during gelling were observed in the case of insoluble fillers. 
Polymeric excipients 
A study reported that non-ionic polymers did not alter drug release 
significantly from HPMC matrices; however, ionic polymers were capable of 
retarding the release of oppositely charged molecules. They studied the effect of 
polymeric additives (non-ionic polyethylene glycol 6000 or ethyl cellulose, cationic 
diethylaminoethyl dextran, anionic sodium carboxymethyl cellulose Na-CMC) on 
drug release (chlorpheniramine maleate, sodium salicylate and 
potassiumfenoxymethylpenicillin) from HPMC matrix (85%). Non-ionic polymers 
(15% of tablet weight) did not significantly alter the release rates. Na-CMC (50% 
replacement of HPMC) reduced the chlorpheniramine maleate release in pH 7 buffer 
(near zero order release), but not in an acidic medium. There was a complexation of 
the drug with the anionic polymer; which was not possible below pH 3, when Na-
CMC  was  in  its  unionized  insoluble  form.  As  a  result  of  the  complexation,  the  gel  
erosion became the prominent release mechanism instead of diffusion. No interaction 
occurred between sodium salicylate and Na-CMC (both anionic). In the presence of 
diethylaminoethyl dextran, sodium salicylate release was slower at pH 7, but not 
altered at pH 1 (when the drug was present in its unionized form). Overall, the effect 
of ionic polymers incorporated into HPMC matrices on the release of oppositely 
charged drugs was small. The drug-polymer ionic complexation approach in 
designing oral dosage formulation for controlled release of buspirone. Anionic 
exchange polymers sodium carboxymethyl cellulose and methacrylic acid 
/ethylacrylate copolymer were recommended based on the complexation affinity and 
dispersability in the aqueous environment of the gastrointestinal tract. The weight 
ratio of buspirone to anionic exchange polymer varied between 4:1 and 1:6, 
preferably between 2:1 and 1:4. In addition to facilitating the controlled release of 
buspirone, the formulations increased the bioavailability and reduced the inter-
individual variability. Therefore, the buspirone-ion exchange polymer HPMC tablet 
permitted enhanced targeting of therapeutic amounts and effects of the drug. The 
addition of anionic polymers (Eudragit® S, Eudragit® L 100-55, and Na-CMC) on 
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the release of weakly basic propranolol hydrochloride from HPMC matrices. The 
interaction between propranolol hydrochloride and anionic polymers influenced the 
drug  release.  The  HPMC:  anionic  polymer  ratio  also  affected  the  drug  release.  The  
matrix containing HPMC: Eudragit® L 100-55 (1:1) produced pH-independent 
extended release tablet. An optimization procedure to determine the HPMC: e-
carrageenan ratio (34:30) required for a pH-independent release of chlorpheniramine 
maleate. e-Carrageenan was added to overcome the increase in diffusion path length 
and decrease in the release rate associated with HPMC systems. e-carrageenan was 
subjected to erosion, which was higher at acidic pH. 
1.11.3 PROCESS VARIABLES 
A) Compression force:  
The compression force had a significant effect on tablet hardness; its effect on 
drug release from HPMC tablet was minimal. It could be assumed that the variation in 
compression force should be closely related to a change in the porosity of the tablet. 
However, as the porosity of the hydrated matrix is independent of the initial porosity, 
the compression force seems to have little influence on drug release. The changes in 
compression force or crushing strength had minimal effect on drug release from 
HPMC matrix tablet once critical hardness was reached. Increased dissolution rates 
were observed when the tablets were found to be extremely soft, and this 
phenomenon was  attributed  to  a  lack  of  powder  compaction,  as  tablet  hardness  was  
only 3 kp. 
B) Tablet shape: 
The  size  and  shape  of  the  tablet  for  the  matrix  system  undergoing  diffusion  
and erosion might impact the drug dissolution rate. Modification of the surface area 
for metoprolol tartrate tablet formulated with Methocel® K100LV from the standard 
concave shape (0.568 sq. in.) to caplet shape (0.747 sq. in.) showed an approximately 
20-30%  increase  in  dissolution  at  each  time  point.  Based  upon  these  results,  the  
researchers concluded that for maximum uniformity of extended release 
characteristics, tablet matrices should be manufactured to be as spherical as possible, 
in order to produce the minimum release rate, with regard to tablet shape. Varying the 
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aspect  ratio  (radius/height)  of  the  HPMC  tablet  is  a  very  easy  and  effective  tool  to  
modify the release rate of the matrix system. 
Release rate for tablet with the same volume was higher for flat shape (ratio = 
20) than regular cylinders (ratio 2) and almost rod-shaped cylinders (ratio 0.2). The 
results were attributed to difference in tablet surface area. A mathematical model was 
proposed that could employ in order to calculate the optimal aspect ratio and size of a 
cylindrical tablet required to achieve a specific release profile. The model takes into 
account Fickian diffusion of water in and drug out of the tablet and swelling; it does 
not take into account dissolution and it cannot be applied for water insoluble drugs, 
which are released by dissolution process. The mathematical model proposed above 
was then used to predict the dissolution rates of propranolol hydrochloride and 
chlorpheniramine maleate (water soluble drugs). 
C) Tablet size: 
For tablet having the same aspect ratio and drug concentration, the tablet size 
had a very strong influence on the release rate; within 24 hours, 99.8% was released 
from the small tablet, 83.1% from the medium size and 50.9% from the large tablet. It 
was hypothesized that the smaller tablet released drug more rapidly due to an 
increased surface area per volume. Additionally, it was concluded that larger 
diffusion pathways existed in the larger tablet leading to a decrease in drug release. 
1.11.4 BIOLOGICAL PROPERTIES 
I) Absorption: 
The rate, extent and uniformity of absorption of a drug are important factors 
when considering it's formulation into a controlled - release system. Since the rate 
limiting step in drug delivery from a controlled-release system is its release from a 
dosage form, rather than absorption, a rapid rate of absorption of drug relative to its 
release is essential if the 'system is to be successful. In case of controlled release 
dosage form Kr<<< Ka this becomes most critical in the case of oral administration. 
Assuming that the transit time of a drug through the absorption half-life should be to 
4 hrs. This corresponds to a minimum absorption rate constant Ka of 0.17 to 0.23 hr 
necessary for about 80 to 95 % absorption over a 9 to 12 hr transit time. For a drug 
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with a very rapid rate of absorption, (i.e. Ka >>0.23 hr-1), the above discussion 
implies  that  a  first  order  release  rate  constant  Kr  <  0.17  hr-1  is  likely  to  result  in  
unacceptable poor bioavailability in many patients. Therefore, slowly absorbed drugs 
will be difficult to formulate into controlled release systems where the criteria that Kr 
<<< Ka must be met. 
II) Distribution: 
The distribution of a drug into vascular and extravascular spaces in the body is 
an important factor in its overall elimination kinetics. Two parameters that are used to 
describe the distribution characteristics of a drug are its apparent volume of 
distribution and the ratio of drug concentration in the tissue is that in plasma at the 
steady state called T/P ratio. The magnitude of the apparent volume of distribution 
can be used as a guide for additional studies and as a predictor for a drug dosing 
regimen and hence there is a need to employ a controlled-system. 
III) Metabolism: 
Drugs that are significantly metabolized before absorption, either in the lumen 
or: tissue of the intestine can show decreased bioavailability from slower-releasing 
dosage forms. Most intestinal wall enzyme systems are saturable. As the drug is 
released at a slower rate to these regions, less total drug is presented to the enzymatic 
process during a specific period allowing more complete conversion of drug to its 
metabolite. Formulation of these enzymatically susceptible compounds as prodrug is 
another viable solution. 
IV) Biological Half Life: 
The usual goal of an oral sustained release product is to maintain therapeutic 
blood levels over an extended period. To this, drug must enter the circulation at 
approximately the same rate at which it is eliminated. The elimination rate is 
quantitatively described by the half-life. Each drug has its own characteristics 
elimination rate, which is the sum of all elimination processes including metabolism, 
urinary excretion and all other processes that permanently remove drug from blood 
stream. Therapeutic compounds with short half-life are excellent candidates for 
sustained-release preparations, since this can reduce dosage frequency.  However, this 
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is limited, in that drugs with very short biological half life as it may require 
excessively large amounts of drug in each dosage unit to maintain sustained effect, 
forcing the dosage form itself to become limitingly large. 
In general, drugs with half-life shorter than two hrs are poor candidates for 
sustained release preparations. Drugs with long half-life, more than 8 hrs, are also 
generally does not be used in sustaining forms, since their effect is already sustained. 
V) Side Effects and Safety Considerations: 
          There are very few drugs whose specific therapeutic concentrations are 
known. Instead, a therapeutic concentration range is listed, with increasing toxic 
effects expected above this range and a fall off in desired therapeutic response 
observed below the range. 
The most widely used measure of the margin of safety of a drug is its 
therapeutic index, (Tl). 
TI =   LD50/ ED50 
       Where,  
         LD50 = median lethal dose 
         ED50 = median effective dose 
       For very potent drugs, whose therapeutic concentration range is narrow, the 
value TI is  small.  In general,  larger the value of TI,  Usually are poor candidates for 
formulation into controlled-release product. A drug is considered to be relatively safe 
if its TI value exceeds 10. 
VI) Dose Size: 
Since a controlled-release system is designed to alleviate repetitive dosing, it 
is naturally contain greater amount of drug that a corresponding conventional dosage 
form. For lose drugs requiring large conventional doses, the volume of sustained dose 
may be so large so to be impractical or unacceptable, depending on the route of 
administration. The same may be true for drugs that require a large release rate from 
the controlled-release system, e.g., drugs with shorter half-life. For oral route, the 
volume of the product is limited by patient acceptance. 
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2. AIM AND OBJECTIVE 
The  aim  of  this  study  is  to  develop  the  extended  release  tablet  of  
Trimetazidine HCL for the potential treatment of Angina Pectorise. 
2.1 REASONS FOR SELECTION OF TRIMETAZIDINE HCL:- 
Ø Trimetazidine HCL (TMZ), the antianginal compound approved for 
clinical use is widely used for treatment of antianginal either alone or in 
combination with other antianginal agents. 
Ø However, the main limitation to therapeutic effectiveness of TMZ is its 
dose-dependent hematological toxicity, low therapeutic index, short 
biological half-life, and poor bioavailability.  
Ø After oral administration, it is rapidly absorbed from the gastrointestinal 
tract (GIT) exhibiting a peak plasma concentration of 84 ng/ml at 1.8+/- .7 
hrs hours. The biological half-life of TMZ is 6 hours, thus necessitating 
frequent administration (3 to 4 times a day) to maintain constant 
therapeutic drug levels. 
 2.2 REASONS FOR SELECTION OF DOSAGE FORM 
Ø The goal of any drug delivery system is to provide a therapeutic amount of 
drug to the proper site in the body to promptly achieve and maintain the 
defined drug concentration. 
Ø In pharmaceutical practice, drug administration to patient exists in several 
approaches, one of which is conventional, i.e. drug is given several times a 
day, to produce desired therapeutic effect. 
Ø Due to frequent dosing, fluctuation in the drug blood level occurs; hence 
maintenance of defined drug level can be above or below the minimum 
therapeutic level. The conventional tablet provides only a single transient 
release of drug. 
Ø Hence the above potential problem can be minimized or reduced by 
formulating the drug in release control matrix i.e. sustain release 
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system.This system minimizes or eliminates side effects, provide patient 
compliance, economically and promptly achieves and maintains the 
desired effect. 
Hence due to above properties, it may be more efficient to deliver the drug at a 
sustained  manner, at a reduced input rate compared with oral conventional dose 
occurring from a conventional release dosage form Trimetazidine HCL is available in 
market, presently. 
 2.3 The main objective of present study:- 
v The present study  is to investigate the possibility of developing extended 
release dosage form for the drug Trimetazidine Hcl by using combined 
polymers i.e. HPMC k15CR with Ethyl cellulose, Metalose 
(Hypermellose) with Ethyl cellulose, HPMC k15CR with Metalose and 
Etyl Cellulose in different ratios as matrix 
v It can be achieved by planning for trails until the desired release pattern is 
obtained. The aim is to evaluate the release profile of drug from fabricated 
extended release matrix tablets. 
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3. PLAN OF WORK 
I. Literature survey 
II. Preformulation studies - 
· Bulk density 
· Tapped density 
· Carr’s Index (Compressibility Index)  
·  Hausner’s Ratio 
· Determnation of  λ max 
· Drug excipients compatibility study by IR spectra 
III. Preparation of Matrix tablets by using matrix forming polymers 
· Method 
Ø By Wet granulation method 
IV. Evaluation of Matrix tablets by 
·  Thickness 
·  Hardness 
·  Weight variation 
·  Friability 
·  In-vitro drug release study 
·  Swelling Index 
  V. Stability study. 
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4. REVIEW OF LITERATURE 
Review of literature showed that the matrix formulation for oral 
administration of many drugs are tried using various polymers and other release 
retardants 
P. D. NAKHAT et.al. “Developing sustained release matrix tablets of 
diclofenac sodium by using different drug: polymer ratios. Xanthan gum w as used as 
matrix former, and microcrystalline cellulose as diluent. All the lubricated 
formulations were compressed using 8 mm flat faced punches. Hence, Xanthan gum 
can be used as an effective matrix former, to extend the release of diclofenac 
sodium”. 
  Chowdary KPR et al. “Olibanum and its resin and carbohydrate fractions were 
evaluated as rate controlling matrix materials in tablets for controlled release of 
diclofenac. Diclofenac matrix tablets were formulated employing olibanum and its 
resin and carbohydrate fractions in different concentrations and the tablets were 
evaluated for various tablet characters including drug release kinetics and mechanism. 
Diclofenac matrix tablets formulated employing olibanum and its resin component 
provided slow and controlled release of diclofenac over more than 24 h. Drug release 
from the matrix tablets was by Fickian diffusion and followed first order kinetics”. 
  S C Basak et al. “Monolithic matrix tablets of ambroxol hydrochloride were 
formulated as sustained release tablets employing hydroxypropyl methylcellulose 
polymer, and the sustained release behaviour of the fabricated tablets was 
investigated. Sustained release matrix tablets containing 75 mg ambroxol 
hydrochloride were developed using different drug polymer ratios of hydroxypropyl 
methylcellulose”. 
J.P.G. Brakenhoff et  al.  “The  effect  of  age  and  renal  function  on  the  
pharmacokinetic profile of a modified release tablet of trimetazidine (TMZ MR 35 
mg) administered twice daily. 
             Methods- Study 1: Twelve healthy elderly subjects (CLcreat 72±8 ml/min, 
72±4 years mean±SD) and eight young volunteers (CLcreat 134±18 ml/min, 25±8 
years) received TMZ MR 35 mg b.i.d. (eight doses). Study 2: eight patients with 
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severe renal failure (CLcreat. 17±5 ml/min, 54±10 years), five patients with moderate 
renal failure (CLcreat. 39±6 ml/min, 54±15 years) and eight volunteers (CLcreat. 104±17 
ml/min, 53±9 years) received TMZ MR 35 mg b.i.d. (patients: ten doses, volunteers: 
eight doses). Serial blood and urine samples were obtained following administration 
of the last dose in each study. TMZ plasma and urine concentrations were determined 
by gas chromatography (NPD-detector). The resulting data were analysed using 
standard non-compartmental pharmacokinetic methods”. 
Basak SC et al. “Monolithic matrix tablets of ambroxol hydrochloride were 
formulated as sustained release tablets employing hydroxypropyl methylcellulose 
polymer, and the sustained release behaviour of the fabricated tablets was 
investigated. The results of dissolution studies indicated that a decrease in release 
kinetics of the drug was observed on increasing polymer ratio. The mechanism of 
drug release from the optimized formulation was diffusion coupled with erosion 
(anomalous)”. 
R.K.Khar et al. “Compressed tablets were prepared from theophylline and 
guar  gum.  Effect  of  the  viscosity  grade  of  the  polymer  and  polymer  content  in  the  
tablets on release pattern of theophylline was examined in vitro. Release rate was 
retarded with increase in polymer content as well as the viscosity grade of polymer”. 
M. Marzilli et al. “The efficacy of trimetazidine as an antianginal drug has 
been assessed in randomized, placebo-controlled studies, both as ‘solo’ treatment and 
in combination with betablockers and calcium channel blockers.In patients with 
chronic angina, trimetazidine increases work capacity and delays the appearance of 
symptoms  and  ECG   changes  during  exercise.  The  benefits  observed  after  acute  
administration are maintained in chronic treatment with trimetazidine, which is well 
tolerated by patients”. 
Balasubramaniam et  al. “Matrix tablets of cisapride and atenolol were 
prepared with varying proportions of hydroxypropylmethylcellulose of different 
viscosity grades viz; E15,E4M, K4M, And K15M, alone and combinations by wet 
granulation technique. The study also indicated that the amount of drug released 
decreased with an increase the polymer concentration. The combination of the 
different viscosity grades did not provide any additional advantage”. 
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P D Nakhat  et  al.“In  the  present  investigation,  an  attempt  has  been  made  to  
increase therapeutic efficacy, reduce frequency of administration, and improve patient 
compliance, by developing sustained release matrix tablets of diclofenac sodium. 
Sustained release matrix tablets of diclofenac sodium, were developed by using 
different drug: polymer ratios, such as F1 (1:0.12), F2 (1:0.16), F3 (1:0.20), F4 
(1:0.24) and F5 (1:0.28). Xanthan gum was used as matrix former, and 
microcrystalline cellulose as diluent. All the lubricated formulations were compressed 
using 8 mm flat faced punches”.  
Haider S.S. et al. “ Sustained release preparetations of metoclopramide HCl 
were prepared using carnauba wax and stearic acid as matrix formers. Granules were 
prepared by melt dispersion method while tablets were made by direct compression”.  
The fastest release rate was observed at pH 4.5 and the slowest at pH 1.2 
which coincides with the drug's solubility behavior. The drug release kinetics 
followed the Higuchi's square root model in all cases 
Rathnanand M. et al. studied to develop sustained release matrix tablets of 
Terbutaline Sulphate.The tablets were prepared by wet granulation method using 
isopropyl alcohol with stearyl alcohol as granulating agent. Hydrophilic matrix 
materials like hydroxypropylmethylcellulose(HPMC), hydrophobic polymer such as 
Eudragit RLPO where used in the study. All the formulations exhibited Higuchi-
dominated drug release. The mechanism of drug release was found to be diffusion 
controlled. 
Thapa  P.  et  al.  studied  the  effect  of  different  viscosity  grade  of  HPMC  and  
drug solubility on in-vitro release from matrix tablets. In addition to release 
mechanism, the release rate and mean dissolution time for propranolol HCl, salicylic 
acid and furosemide was compared using Krosmeyer-peppas equation. The release 
mechanism was found to be predominately diffusion controlled, anomalous, and case 
II transport type.  
Nashiru Billa et al. studied processing variables at the laboratory and pilot 
scales that can affect hydration rates of xanthan gum matrices containing diclofenac 
sodium and the rate of drug release. Drug release was linear from xanthan gum 
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matrices prepared at the laboratory scale and pilot scales; however, release was faster 
from the pilot scales.  
M. Helena Amaral et al. “effect of the concentration of hydrophilic (hydroxyl 
propyl methyl cellulose [HPMC] and hydrophobic (hydrogenated castor oil [HCO] 
products, fillers (lactose and dibasic calcium phosphate), and buffers (sodium 
bicarbonate, calcium carbonate, and sodium citrate) on naproxen release rate was 
studied. 
Robert  O.Williams  III  et  al.  studied  a  reverse-phase  high-performance  liquid  
chromatographic (HPLC) method for recovery of the lipophilic drug, alprazolam, 
from matrix tablets containing the hydrophilic polymer 
hydroxylpropylmethylcellulose (HPMC) was developed. The recovery method 
reported here in was shown to be the most efficient to achieve complete recovery of 
alprazolam from powder blends and tablets containing a variety of excipients and 
different grades of HPMC. 
Sandip B. Tiwari et al. studied the effect of concentration of hydrophilic (hy-
droxypropyl methylcellulose [HPMC]) and hydrophobic polymers (hydrogenated 
castor oil [HCO], ethylcellulose) on the release rate of tramadol were studied. 
Hydrophilic matrix tablets were prepared by wet granulation technique, while 
hydrophobic (wax) matrix tablets were prepared by melt granulation technique. 
Hydro-phobic matrix tablets resulted in sustained in vitro drug release (>20 hours) as 
compared with hydrophilic ma-trix tablets (<14 hours). The presence of ethylcellulose 
in either of the matrix systems prolonged the release rate of the drug. 
K. Raghuram Reddy et al. studied to develop once-daily sustained-release 
matrix tablets of nicorandil, a novel potassium channel opener used in cardiovascular 
diseases. The tablets were prepared by the wet granulation method. Ethanolic 
solutions of ethylcellulose (EC), Eudragit RL-100, Eudragit RS-100, and 
polyvinylpyrrolidone were used as granulating agents along with hydrophilic matrix 
materials like hydroxypropyl methylcellulose (HPMC), sodium 
carboxymethylcellulose, and sodium alginate. The results of dissolution stud-ies 
indicated that formulation (drug-to-HPMC, 1:4; ethanol as granulating agent) could 
extend the drug release up to 24 hours.  
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Svetlana Ibric et al.   studied  to model the effects of the concentration of Eudragit L 
100 and compression pressure as the most important process and formulation 
variables on the in vitro release pro-file of aspirin from matrix tablets formulated with 
Eudragit L 100 as matrix substance and to optimize the formulation by artificial 
neural network. 
Srisagul  Sungthongjeen  et  al.  “Effect  of  2  formula-tion  variables,  the  pectin  
type  (with  different  degrees  of  es-terification  [DEs]  and  the  amount  of  calcium,  on  
drug re-lease from pectin-based matrix tablets. The results were more pronounced in 
phosphate buffer, where the phosphate ions induced the pre-cipitation of calcium 
phosphate. In conclusion, both pectin type and added calcium affect the drug release 
from the pec-tin-based matrix tablets”. 
Meena Rani et al. studied to Prepared and comparative evaluation of 
fabricated matrix (FM), osmotic matrix (OM), and osmotic pump (OP) tablets for 
controlled delivery of diclofenac sodium (DS). It was concluded that the osmotic 
matrix and osmotic pump tablets could provide more prolonged, controlled, and 
gastrointestinal environmental independent DS release that may result in an improved 
therapeutic efficacy and patient compliance. 
Saleh M. Al-Saidan et al. “Develop guar gum matrix tablets for oral controlled 
release of water-soluble diltiazem hydrochloride. Matrix tablets of diltiazem 
hydrochloride, using various viscosity grades of guar gum in 2 proportions, were 
prepared by wet granulation method and subjected to in vitro drug release studies. 
Based on the results of in vitro and in vivo studies it was concluded that that guar 
gum matrix tablets provided oral controlled release of water-soluble diltiazem 
hydrochloride”. 
Mohammad Reza Siahi et al.  “Design oral controlled delivery systems for the 
water-soluble drug, verapamil hydrochloride, using natural and semisynthetic 
polymers as carriers in the forms of 1- and 3-layer matrix tablets. Verapamil 
hydrochloride 1-layer matrix tablets containing hydroxylpropylmethylcellulose, 
tragacanth, and acacia either alone or mixed were prepared by direct compression 
technique.  
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The results also showed that the location of the polymers in the 3-layer tablets 
has  a  pronounced  effect  on  the  drug  release.  Kinetic  analysis  of  drug  release  from  
matrices exhibiting sustained release indicated that release was predominantly 
attributable to the contribution made by Fickian diffusion, while the 
erosion/relaxation mechanisms had a minor role in the release”. 
Bhupinder Singh et al.  Design oral controlled release mucoadhesive 
compressed hydrophilic matrices of atenolol and to optimize the drug release profile 
and bioadhesion using response surface methodology. A central composite design for 
2 factors at 3 levels each was employed to systematically optimize drug release 
profile and bioadhesive strength. Carbopol 934P and sodium carboxy methyl 
cellulose were taken as the independent variables. Besides unraveling the effect of the 
2 factors on the various response variables, the study helped in finding the optimum 
formulation with excellent bioadhesive strength and controlled release. 
Jaleh Varshosaz et al.  developed matrix sustained release tablets of highly 
water-soluble tramadol HCl using natural gums (xanthan [X gum] and guar [G gum]) 
as costeffective, nontoxic, easily available, and suitable hydrophilic matrix systems 
compared with the extensively investigated hydrophilic matrices (ie, hydroxypropyl 
methylcellulose [HPMC]/carboxymethyl cellulose [CMC] with respect to in vitro 
drug release rate) and hydration rate of the polymers. Tablets with only X had the 
highest  mean  dissolution  time  (MDT),  the  least  dissolution  efficiency  (DE8%),  and  
released the drug following a zero-order model via swelling, diffusion, and erosion 
mechanisms. Guar gum alone could not efficiently control the drug release, while X 
and all combinations of natural gums with HPMC could retard tramadol HCl release. 
However, according to the similarity factor ( f2), pure HPMC and H8G2 were the 
most similar formulations to Topalgic-LP as the reference standard. 
Carla Martins Lopes et al. was studied to produce a quick/slow biphasic 
delivery system for ibuprofen. A dual component tablet made of a sustained release 
tableted core and an immediate release tableted coat was prepared by direct 
compression. Both the core and the coat contained a model drug (ibuprofen). The 
sustained release effect was achieved with a polymer (hydroxyl propyl 
methylcellulose [HPMC] or ethyl cellulose) to modulate the release of the drug. The 
in vitro drug release profile from these tablets showed the desired biphasic release 
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behavior: the ibuprofen contained in the fast releasing component was dissolved 
within 2 minutes, whereas the drug in the core tablet was released at different times 
(≈16 or 924 hours), depending on the composition of the matrix tablet. Based on the 
release kinetic parameters calculated, it can be concluded that the HPMC core was 
suitable for providing a constant and controlled release (zero order) for a long period 
of time. 
Amelia Avachat et al. Develop and characterize an oral controlled release drug 
delivery system for concomitant administration of diclofenac sodium (DS) and 
chondroitin sulfate (CS). A hydrophilic matrix-based tablet using different 
concentrations of hydroxyl propyl methylcellulose (HPMC) was developed using wet 
granulation technique to contain 100 mg of DS and 400 mg of CS. In conclusion, the 
in vitro release profile and the mathematical models indicate that release of CS and 
DS can be effectively controlled from a single tablet using HPMC matrix system.  
Hamdy Abdelkader et al. was investigating different types and levels of 
hydrophilic matrixing agents, including methylcellulose (MC), sodium alginate (Alg), 
and sodium carboxy methylcellulose (CMC), in an attempt to formulate controlled-
release matrix tablets containing 25 mg baclofen. The tablets were prepared by wet 
granulation. Prior to compression, the prepared granules were evaluated for flow and 
compression characteristics. In vitro, newly formulated controlled-release tablets were 
compared with standard commercial tablets (Lioresal and baclofen). The prepared 
matrix tablets showed good mechanical properties (hardness and friability). MC- and 
Alg-based tablet formulations showed high release-retarding efficiency, and good 
reproducibility and stability of the drug release profiles when stored for 6 months in 
ambient room conditions, suggesting that MC and Alg are good candidates for 
preparing modified release baclofen tablet formulations 
Atul Kuksal et al. was studied to prepare and characterize extended-release 
matrix tablets of zidovudine using hydrophilic Eudragit RLPO and RSPO alone or 
their combination with hydrophobic ethyl cellulose. Release kinetics was evaluated 
by using United States Pharmacopeia (USP)-22 type I dissolution apparatus. The in-
vitro drug release study revealed that either Eudragit preparation was able to sustain 
the drug release only for 6 hours (94.3% ± 4.5% release). Combining Eudragit with 
ethyl cellulose sustained the drug release for 12 hours (88.1% ± 4.1% release). Fitting 
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the in vitro drug release data to Korsmeyer equation indicated that diffusion along 
with erosion could be the mechanism of drug release. In vivo investigation in rabbits 
showed sustained-release pharmacokinetic profile of zidovudine from the matrix 
tablets formulated using combination of Eudragits and ethylcellulose. In conclusion, 
the results suggest that the developed sustained-release tablets of zidovudine could 
perform therapeutically better than conventional dosage forms, leading to improve 
efficacy and better patient compliance. 
Punna  R.  R.  et  al.  ,Oral  controlled  release  matrix  tablets  of  zidovudine  were  
prepared using different proportions and different viscosity grades of hydroxypropyl 
methylcellulose. The effect of various formulation factors like polymer proportion, 
polymer viscosity and compression force on the in vitro release of drug were studied. 
In vitro release studies revealed that the release rate decreased with increase in 
polymer proportion and viscosity grade. Mathematical analysis of the release kinetics 
indicated that the nature of drug release from the matrix tablets followed non-Fickian 
or anomalous release. The developed controlled release matrix tablets of zidovudine, 
with good initial release (17—25% in first hour) and which extend the release upto 
16—20 h, can overcome the disadvantages of conventional tablets of zidovudine. 
Nokheldchi  A.  et  al.,  The  effects  of  various  polymers  on  the  release  of  
Diclofenac Sodium from matrics. In vitro release profile of Diclofenac Sodium from 
ethyl cellulose and HPMC K4M matrices showed that decreasing the concentration of 
Ethyl Cellulose and increase in the concentration of HPMC K4M resulted in an 
increase in the release rate of Diclofenac Sodium.   
B.S. Nath et.al.,The using a combined hydrophobic and hydrophilic matrix on 
the release of  Theophylline. Combination of aliphatic alcohol (cetyl alcohol (cetyl 
alcohol) partially hydrated Methylcellulose was investigated as a sustain release 
matrix. The in-vitro release data showed that the total matrix component gave 
extended release of Theophylline for more than 8 hours and the drug release from the 
matrix indicated that the drug was released by diffusion obeying first order rate 
kinetics. 
Chowdary K.P.R. et al. , Sustained release of Nifedipine tablets by using 
soliddispersion in HPMC with HPC and reported that its gave slow, controlled and 
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complete release spread over a period of 12 hours. Drug release from these tablets 
followed zero order kinetics and release was by diffusion controlled. 
M. Helena Amaral et al., The effect of the concentration of hydrophilic 
(hydroxypropyl methylcellulose [HPMC]) and hydrophobic (hydrogenated castor oil 
[HCO]) products, fillers (lactose and dibasic calcium phosphate), and buffers (sodium 
bicarbonate, calcium carbonate, and sodium citrate) on naproxen release rate was 
studied. Matrix tablets were prepared by double compression, and In vitro dissolution 
tests were performed. The dissolution results showed that an increased amount of 
HPMC or hydrogenated castor oil resulted in reduced drug release. 
Efentakis M., et al., The effect of excipients on swelling and drug release from 
compressed matrices. The result showed that mechanisms are affected by the 
composition of matrix. 
Efentakis. et al., The influence of surfactant on drug release from a 
hydrophobic matrix. Hydrophobic materials were prepared using Eudragit R.L-100 
and Flurbiprofen as a model drug and studied to determine the mechanism by which 
surfactant increase the rate of drug release. It was concluded that for the matrix the 
major mechanism by which surfactant increase drug dissolution rates is through the 
formation  of  pores  to  aid  the  access  of  dissolution  fluid  and  egress  of  the  dissolved  
drug. 
Rippe EG, et al., A stabilized sustained release oral solid dosage form which 
includes an effective amount of tramodol or pharmaceutically acceptable salt therfof 
dispersed in matrix of a hydrophobic material comparising a wax-like substance 
which was melted or softened during the preparation of the matrix,is cured at a 
temperature from about 35 0 C to 65 0 C for a time period from about 4 to about 72 
hour, such that the  formulation. 
Skoug  J.W.  et  al.,  The  quantities  evaluation  of  the  mechanism  of  release  of  
matrix sustained release dosage forms by measurement of polymer release. 
Hsieh et al., Reported a more elegant version of this device which utilized an 
inward releasing hemisphere. This hemisphere was coated with an impermeable 
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membrane barrier everywhere except a small aperture in the center of this circular 
face. Such a device has been applied to polypeptide hormone insulin.  
Kawasheina I. et al. ,A modified spherical agglomeration technique as an 
alternative to spray congealing method. The method of preparation will influence the 
releasing characteristics obtained. 
Chinam Niranjan Patra et al. ,Develop a bilayer tablet of propranolol 
hydrochloride using superdisintegrant sodium starch glycolate for the fast release 
layer and water immiscible polymers such as ethylcellulose, Eudragit RLPO and 
Eudragit RSPO for the sustaining layer. The formulations gave an initial burst effect 
to provide the loading dose of the drug followed by sustained release for 12 h from 
the sustaining layer of matrix embedded tablets. In vitro dissolution kinetics followed 
the Higuchi model via a non-Fickian diffusion controlled release mechanism after the 
initial burst release. 
Teerawat Sahasathian et al., The Sustained release systems in the forms of 
chitosan (CTS) tablet and extrude for releasing amoxicillin. The result showed that 
chitosan with the particle size less than 75 μm yielded the best controlled release 
pattern. Moreover, the tablets containing chitosan with particle size less than 75 μm 
were able to provide a significantly improved sustained release profile of amoxicillin 
compared to the release profile of a commercial capsule. 
S.  Prasanna  et.  al.,  “To  develop  “once  daily”  sustained  release  tablets  of  
aceclofenac by direct compression using hydroxypropyl methylcellulose-K4M 
(HPMC).  The  solubility  studies  of  aceclofenac  were  conducted  to  select  suitable  
dissolution media. The tablets were subjected to physicochemical, in vitro drug 
release and stability studies”. 
It  was  observed  from the  reviewer  of  literature  that  very  less  work  has  been  
done on the formulation of matrix devices of Zidovudine. So, it was proposed to take 
Zidovudine in the present study of formulation of matrix tablet. Further it was 
proposed to use Xanthan, Ethyl cellulose, Hydroxy propyl methyl cellulose (E.Lv-
15), Carboxy Methyl cellulose Sodium and Eudragit L155 as polymer is very less 
work has been done on above polymers. 
 
 
 
 
 
 
 
 
 
 
 
 
DRUG PROFILE 
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5.1 DRUG PROFILE   
 
Figure No.5:- Structure of Trimetazidine HCL 
 
 Drug Name       : Trimetazidine HCL  
Chemical Name: 1-(2, 3, 4-Trimethoxybenzyl) piperazine hydrochloride. (TMZ).  
Molecular Formula: (C14H22N2O3 ) 2HCL 
Molecular Weight   : 339.26 g/mol. 
Category: Antianginal (vasodilator) Trimetazidine (Di HCl) is used in angina and in 
ischaemia  of  neuro-sensorial  tissues.To  prevent  the  pain  of  chest  due  to  lack  of  
oxygen to the muscles of heart. 
Solubility: very soluble in water, sparingly soluble in ethanol and practically 
insoluble in ether. 
Melting Point:  227°C. 
PHARMACOKINETICS: 
PHARMACOKINETIC DATA:  
v Bioavailability-  90% 
v Protein binding –16% 
v Metabolism - hepatic 
v Half life – 6.0 +/- 1.4 hours 
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v Excretion -  urinary  
v Peak plasma concentration – 84 ng/ml  
v T max – 1.8+/- .7 hrs 
v Duration of action – 4 hrs or longer 
v Volume of distribution is found to be 4.8 l/kg and plasma protien binding is 16 
%.  
PHARMACOLOGY: 
Trimetazidine, known for years to be an effective antianginal agent, shifts 
cardiac energy metabolism from fatty acid oxidation to glucose oxidation by 
inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. By decreasing 
fatty acid oxidation, trimetazidine stimulates glucose utilization, restoring coupling 
between glycolysis and carbohydrate oxidation and leading to adenosine triphosphate 
production with lesser oxygen consumption. The antianginal properties of this agent 
are devoid of haemodynamic changes, and dramatically improve recovery of 
mechanical function after ischemia. 
MECHANISM OF ACTION: 
It has recently been demonstrated that, by inhibiting mitochondrial long-chain 
3-ketoacyl coenzyme A thiolase, trimetazidine alters energy metabolism via 
inhibitory effects on fatty acid oxidation, thus favouring glucose oxidation. On the 
basis of this recent observation, trimetazidine is regarded as the prototype of a new 
class of antianginal agents: the 3-ketoacyl coenzyme A thiolase inhibitors. The 
benefits of increased glycolytic substrate utilization are attributed to a number of 
mechanisms. The number of moles of adenosine triphosphatase (ATP) produced per 
mole of carbon oxidized is approximately 29% higher for free fatty acids relative to 
glucose, but the number of moles of ATP produced per mole of oxygen consumed is 
12% higher for glucose than for free fatty acid oxidation. Thus, in normal conditions, 
it is more efficient for the myocardium to utilize free fatty acids, but during ischaemia 
glucose is a better substrate. By decreasing fatty acid oxidation and stimulating 
glucose utilization, trimetazidine restores coupling between glycolysis and 
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carbohydrate oxidation, and leads to ATP production with less oxygen consumption. 
By stimulating membrane phospholipid turnover during ischaemia and reperfusion, 
trimetazidine redirects fatty acids toward phospholipids. 
SIDE EFFECTS: 
Trimetazidine hydrochloride is safe & well tolerated. In addition, the toxic 
dose being very high, the safety margin of this drug is wide. The most commonly 
encountered side effects are gastric discomfort, nausea, headache and vertigo. 
INTERACTIONS: 
No drug interactions so far have been reported .in particular no interactions 
have been reported with beta-blockers, calcium antagonists, nitrates, heparin, 
hypolipidemic agents or digitalis praparations.                                                       
 
 
 
 
 
 
 
 
 
 
 
 
POLYMER PROFILE 
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5.2 POLYMER PROFILE  
 
1. HYDROXY PROPYL METHYL CELLULOSE K15CR (HPMC K15CR) 
Non-Proprietary Names: 
BP            : Hypromellose  
Ph Eur   : Methyl hydroxy propyl cellulosum  
USP          : Hydroxy propyl methyl cellulose  
Synonyms:  
 Cellulose, hydroxypropyl methyl ether, culminal MHPC; E-464, HPMC; 
Methocel; methyl cellulose propylene glycol ether, methyl hydroxypropylcellulose, 
Metolose, Pharmacoat.  
Chemical Name: Cellulose, 2-hydroxypropyl methyl ether.  
Empirical Formula & Molecular Weight : 
According to European Pharmacopoeia:  
It is a partly O-methylated & O-(2-hydroxypropylated) cellulose. 
Available in several grades with different viscosity and extent of substitution. 
Grades may be distinguished by appending a no. indicative of the apparent viscosity, 
in mpas, of a 2% w/w aqueous solution at 200C.  
According to USP XXII:  
It specifies the substitution type by appending a 4-digit number to a non-
proprietary name, e.g. HPMC1828. First 2 digits refers approximate % of methoxy 
group (-OCH3) & last 2 digits refers approximate % of hydroxy propoxy group (-
OCH2CHOHCH3) calculated on dried basis. Molecular weight is 10,000-1, 50,000 
gm/mol.  
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Functional Category: 
Coating agent, film former, stabilizing agent, suspending agent, tablet binder, 
viscosity – increasing agent. 
Application in Pharmaceutical Formulation / Technology:  
Ø Widely used in oral & topical pharmaceutical formulation.  
Ø In oral product, HPMC is generally used as tablet binder, in film coating & as an 
extended release matrix tablets 2-5% w/w concentration is suitable as binder in 
either wet or dry granulation process.  
Ø High viscosity grades may be used to retard the release of water-soluble drug 
from matrix.  
Ø Depending on viscosity grade concentration between 2-10% w/w used as film 
forming solution to film-coat tablets. Lower viscosity grades are used in 
aqueous film coating solution while higher viscosity grades used with organic 
solvents.  
Ø Also used as suspending and thickening agent in topical formulation, mainly in 
ophthalmic preparation, as it forms a clear solution with fewer undispersed 
fibers as compared to methylcellulose. So 0.45 –1% w/w used as thickening 
agent to vehicles for eye-drops or artificial tear solution.  
Ø Also used as emulsifier, suspending agent & stability agent in topical gels & 
ointments. As a protective colloid it can also prevent droplets & particles to 
coalescing or agglomerating, thus inhibits sediment formation.   
Ø Also used as adhesive in plastic bandage & wetting agent in topical gels & 
Ointments. As a protective colloid it can also prevent droplets and particles to 
coalescing or agglomerating, thus inhibits sediment formation. Also used as 
adhesive in plastic bandage & wetting agent for hard contact lenses. Widely 
used in cosmetics & food products. 
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Description: Odorless & tasteless, white or creamy-white colored fibrous or granular                 
powder.  
Solubility:  
In cold water forms viscous colloidal solution, practically insoluble in 
chloroform (CHCl3), ethanol (95%) & water, but soluble in mixture of ethanol & 
dichloromethane. 
Incompatibility: 
It is incompatible with some oxidizing agent. As at is nonionic it can’t 
complex with metallic salts and ionic organics to form insoluble points.  
Stability & Stability Condition:  
It is a stable material but hygroscopic after drying. Solutions are stable 
between pH 3-11. Increase in temperature decreases viscosity of solution, as it 
undergoes a reversible sol to gel transformation upon heating and cooling respectively 
and get point is 50-900C. Aqueous solutions are enzyme resistant, provide good 
viscosity during long-term storage, but aqueous solution liable to microbial 
contamination and should be preserved with an antimicrobial preservative. Stored in a 
well-closed container, in cool & dry place.  
2. ETHYL CELLULOSE 
Nonproprietary Name:  
BP           : Ethyl Cellulose 
Ph Eur    : Ethyl Cellulosum 
USP NF   : Ethyl Cellulose. 
Synonyms: Aquacoat  ; E462 ; Ethocel ; Surelease. 
Chemical Name: Cellulose ethyl ether.  
Empirical Formula & Molecular Weight: Ethyl Cellulose with complete ethoxyl 
substitution (DS=3) is C12H23O6 (C12H22O5)n C12H23O5, where “n” can vary to provide 
a wide variety of molecular weights. 
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Functional Category: Coating agent, flavoring agent, viscosity-increasing agent, 
tablet binder, tablet filler. 
Application in Pharmaceutical Formulations: 
Ø Used as a hydrophobic coating agent for tablets & granules. Ethyl cellulose 
coatings are used to modify the release of a drug, to mask unpleasant taste & 
to improve stability. 
Ø Used as a matrix former to produce modified release tablets. 
Ø High viscosity grades are used in drug micro-encapsulation. 
Ø Used as a SR tablet coating material in a concentration of 2-3%. 
Ø Used as thickening agent in topical formulations. 
Description: It is a tasteless, free flowing, white to light tan-colored powder. 
Solubility: Practically insoluble in glycerin, propylene glycol & water. Ethylcellulose 
that contains less than 46.5% ethoxyl group is freely soluble in chloroform, methyl 
acetate & tetrahydrofuran, in mixtures of aromatic hydrocarbon with ethanol (95%). 
Ethylcellulose that contains not less than 46.5% ethoxyl group is freely soluble in 
chloroform,ethanol (95%), ethyl acetate, methanol & toluene 
Viscosity: Viscosity increases with an increase in the ethyl cellulose concentration. 
Incompatibilities: Incompatible with paraffin wax & microcrystalline wax. 
Stability & Storage Conditions: It shows oxidative degradation in presence of 
sunlight or UV light at elevated temperatures, which can be prevented by the use of 
anti-oxidants & additives that can absorb light at 230-340nm range. It should be 
stored at a temp. not exceeding 32°C (90°F). It shouldn’t be stored next to peroxides 
of other oxidizing agents. 
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3. METALOSE 
Non-Proprietary Name:  
               USP:    Hypermellose 
               Substitution Type:         2208 
               Viscosity Type    :     100  mPa s 
Chemical Name: Cellulose ethyl ether.  
Functional Category: Viscosity-increasing agents, tablet binder, tablet Polymer. 
Application in Pharmaceutical Formulations: 
Ø Used as a hydrophobic coating agent for tablets & granules. Ethyl cellulose 
coatings are used to modify the release of a drug, to mask unpleasant taste & 
to improve stability. 
Ø Used as a matrix former to produce modified release tablets. 
Ø High viscosity grades are used in drug micro-encapsulation. 
Ø Used as a SR tablet coating material in a concentration of 3-5%. 
Ø Used as thickening agent in topical formulations. 
Description:It is a tasteless, free flowing, white to Slightly Off-White Powder. 
Viscosity: Viscosity type 100 mPa s. 
Spesifications: 
Ph       :   5 - 8 
Viscosity:   80   -    120 
Loss on drying:  5.0 max 
Hydroxpropoxy Content:    8.0   -    12.0 
Stability & Storage Conditions: Storage Conditions: Store containers sealed and in 
dry place. Keep away from heat or sunlight. 
 
 
 
 
 
 
 
 
 
 
 
 
EXCIPIENTS PROFILE  
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5.3 EXCIPIENTS PROFILE 
1. STARCH 
Non-Proprietary Name:  
BP               : Maize starch, Potato starch, Wheat starch, Rice starch, Tapioca starch. 
Ph Eur         : Maydis amylum, Solani amylum, Tritici amylum, Oryzae amylum. 
USP NF      : Corn starch, Potato starch, Wheat starch. 
Synonyms:  Amido, amidon, amilo, amylum.  
Chemical Name: Starch. 
Empirical Formula:  C6H10 O5.  
Molecular Weight: 50,000-160,000. 
Functional Category: Glidant and disintegrant; tablet and capsule; tablet binder.  
Application in Pharmaceutical Formulation / Technology:  
It is used as an excipient primarily in oral solid-dosage formulations as a 
binder, diluent, and disintegrant. In tablet formulations, freshly prepared starch paste 
is used at concentration of 5-25% w/w as a binder. Commonly used tablet 
disintegrants at concentrations of 3-15%.   
Description: It occurs as an odorless and tasteless, fine white-colored powder 
comprising very small spherical or ovoid granules whose size and shape are 
characteristic for each botanical variety.    
Moisture Content: 18%for potato starch 
Swelling temperature: 640C 
Solubility: Practically insoluble in cold ethanol (95%) and in cold water.  
Stability and Storage Condition:  Stable and stored in air tight container in a cool 
and dry place. 
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2. MAGNESIUM STEARATE 
Non-Proprietary Name:  
BP          : Magnesium Stearate  
Ph Eur    :  Magnesii Stearas 
USP NF  : Magnesium stearate  
Synonyms: E572, Hy Qual, Magnesium octadecanoate, stearic acid magnesium salts.  
Chemical Name:  Octadecanoic acid magnesium salt  
Empirical Formula: C36H70mg O4 
Molecular Weight:  591.27 
Structural Formula: [CH3 (CH2)16 COO]2Mg 
Functional Category: It is used as tablet and capsule lubricant.  
Application in Pharmaceutical Formulation / Technology:  
2 Used in Cosmetics, foods and pharmaceutical formulations.  
3 Primarily used in capsules and tablets manufacturing at a concentration in 
between 0.25% to 5.0%. 
Description:  
It is a fine, white, precipitated or milled, impalpable, greasy powder of low 
bulk density, having a faint, characteristics odor and taste. It readily adheres to the 
skin.  
Moisture: Content: <4% 
Solubility: Practically insoluble in ethanol (95%), ether and water. Slightly soluble in 
warm benzene and warn ethanol (95%) 
Stability and Storage Condition:  Stable and stored in well closed container in a 
cool and dry place.  
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3. MICROCRYSTALLINE CELLULOSE 
Synonym:  Cellulose gel; crystalline cellulose; Avicel PH 101,102 
Empirical Formula: (C6H10O5)	n	.			 	 	 																																																													 
 Molecular weight: Approx. 36000                                                                               
 Description: Purified, partially depolymerised cellulose occurs as a white, odorless, 
tasteless, crystalline powder composed of porous particles. Available in different 
particle size grades with different properties, i.e., 101 and 102.  
Density, bulk: 0.28 gm/cm3.                                                        
Density, tapped: 0.43 gm/cm3.                                                                                  
 Solubility: Insoluble in water, dilute acids and most organic solvents. slightly soluble 
in sodium hydroxide solution.                                                                                         
Stability & Storage conditions:Stable, hygroscopic,Store in a well-closed container.                                                                                                   
Incompatibilities: None cited in the literature.                                  
Handling precautions: No restrictions.                             
Uses: Tablet binder/diluent(5-20%), tablet disintegrant(5-15%), tablet glidant(5-
15%), anti-adherent(5-20%), capsule diluents (10-30%). 
4. TALC 
        It  is  hydrous  magnesium  silicate  may  contain  a  small  amount  of  aluminum  
silicate and iron.                                                                           
Nonproprietary Name: Purified Talc (BP); Talc (JP); Talc (USP). 
Synonym: Atalc; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
magnesium hydrogen silicate; powdered talc. 
Empirical Formula:  
        Mg6 (Si2O5)4 (OH)4 
Description: A very fine, white to grayish-white, impalpable, odorless, crystalline 
powder. Adheres readily to skin, soft to touch and free from grittiness. 
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Typical Properties: 
Density, bulk: 19-24 gm/cm3. 
Density, tapped: 48-62.5 gm/cm3. 
Acidity/Alkalinity: pH= 7-10 for a 20% w/v aqueous dispersion. 
Solubility:Insoluble in water, organic solvents, cold acids and dilute alkalis.    
Stability & Storage conditions: Talc is a stable material and may be sterilized by 
heating at 1600 C for not less than 1 hour. Talc should be stored in a well-closed 
container in a cool, dry place. 
Incompatibilities: Incompatible with quaternary ammonium compounds. 
Handling Precautions: Observe normal precautions appropriate to the circumstances 
and the quantity of the material handled. Talc is irritant if inhaled and prolonged 
excessive exposure may cause pneumoconiosis. Eye protection, gloves, and a 
respirator are recommended. 
 
Table no. 1:-Application in pharmaceutical formulation or technology: 
Use Concentration (%) 
Dusting powder (90-99%). 
Glidant or tablets lubricant (1-10%) 
Diluents for tablets and capsules (5-30%) 
 
 
5. LACTOSE: 
It occurs in three forms: a-monohydrate, a-anhydrous, b-anhydrous. Commercial 
lactose is mainly the a-monohydrate. 
Chemical name: 4  –  0  -  b-D galactopyranosyl-a-D- glucopyranose.4-(b-D-
galactoside)-D-glucose. 
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Empirical Formula:     Molecular Weight:   
C12H22O11 (anhydrous)    342.30 
C12H22O11H2O (monohydrate)   360.31 
Density (bulk):0.62gm/cm3 
Density (tapped):0.94gm/cm3 
Description: White to off white or creamy white crystalline particles or powder, 
odorless; sweet-tasting. 
Solubility: It is practically insoluble in chloroform, ethanol and ether .soluble in 1in 
4.63parts of water 
Stability and Storage: Store in a well-closed container to prevent absorption of 
moisture  and  of  odors.   Under  humid  conditions  mold  growth  may  occur.   Lactose  
may develop brown coloration on storage.  This reaction is accelerated by warm-
damp conditions. 
Incompatibilities: A mallard type condensation is likely to occur between lactose 
and compounds with a primary amino group to form brown colored products. This 
reaction occurs more rapidly with amorphous then crystalline lactose. 
Handling precautions: Gloves mask and eye protections are recommended. 
Uses: It is used as filler, diluents in pharmaceutical preparation. 
6. COLLOIDAL SILICON DIOXIDE 
Synonyme:Aerosil; cab-o-sil ; colloidal silica ; fumed silica ; silica anhydride. 
Nonproprietary Name: Colloidal anhydrous silica (BP), silica colloidal is androecia 
(Ph Eur), colloidal silicon anhydrous (USP) 
Empirical Formula: SiO2. 
Molecular Weight: 60.08. 
Density (bulk): 0.029-0.042g/cm3. 
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Density (tapped):0.05g/cm3. 
Acidity/Alkalinity: pH= 3.5-4.4 (4% aqueous dispersion) 
Solubility: Practically insoluble in organic solvent, water and acids; soluble in hot 
solution of alkali hydroxide. It forms a colloidal dispersion in water. 
Description: It is submicroscopic fumed silica with a particle size of 15nm. It is light, 
loose, bluish white colored, odorless, tasteless powder. Several grades of colloidal 
silicon dioxides are commercially available. 
Functional Category: Adsorbent; anticacking Agent; emulsion stabilizer, glident; 
suspending agents; disintegrants; thermal stabilizers; viscosity increasing agents. 
Application in Pharmaceutical Formulation or Technology: 
Use           Concentration (%) 
Aerosols     :  0.5-2.0 
Emulsion stabilizer    :  1.0-5.0 
Glidants     :  0.1-0.5 
Suspending and thickening agents   :            2.0-10.0 
Stability and Storage Conditions: Aerosil is hygroscopic but adsorb large quantity 
of water without liquefying. Viscosity-increasing property is depends on pH.Aerosil 
powder should be stored in a well-closed container. 
Incompatibilities: Incompatible with diethylstilbestrol preparations.  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
    MATERIALS AND      
    METHODS 
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MATERIALS AND METHODS 
Table No 2: Materials Used 
S.No Materials Used Monograph Sources 
1. Trimetazidine HCL BP Sharon Bio-Medicine 
LTD. 
2. Ethyl Cellulose USP Feicheng Rutai Fine 
Chemicals CO.Ltd. 
3. Metalose I.P. Arihant trading Co.Ltd. 
4. Hydroxy propyl methyl 
cellulose K-15CR 
I.P. Shineltsu LTD Japan. 
5. Lactose I.P. Berje, Chemical, 
Mumbai 
6. M.C.C. I.P. Relience cellulose Pvt. 
Ltd. 
7. P.V.P.K.30 I.P. Jyoti Associated Indore 
8. Magnesium stearate I.P. Loba Chemie Pvt.Ltd. 
9. Talc I.P. J.B. Chemical. 
10. Pregelatinised Starch  I.P. Loba Chemie Pvt.Ltd. 
11. HCL ------- Laboratory. 
12. Isoprpyl alcohol ------- Laboratory. 
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Table No 3: Instruments Used 
S.No Types Manufactured by 
1. Digital Weighing Balance Ohaus Corp. Pine Brook, NJ, USA. 
2. Hot air oven Unilab, India. 
3 Sieve No; # 12, 16,20, 
60,100. 
Shreeji, Pharmaceutical, Scientific & 
Laboratory Instruments., India. 
4. Compression Machine CIP Machineries Pvt. Ltd., Ahmedabad, 
India. 
5. Roche Friabilator Indian Equipment Corporation, Bombay. 
6. Monsanto Hardness Tester Rupa Industries, India. 
7. Dissolution Test Apparatus Electrolab, Model-TDT-08L, USP. 
8. U.V-Spectrophotometer Shimadzu Corporation, Japan. 
9. Fourier Transform Infra 
Red Spectroscopy (FTIR) 
Nexus-870, Thermo Nicolet, Manisha lab. 
10. Distillation Apparatus Borosil, India. 
11. Water Bath Unilab, India. 
12. Sonicator Spincotech Pvt.Ltd., Italy. 
13. pH-meter Elico Ltd. Hyderabad, India. 
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6.1 Identification of drug (Trimetazidine HCL) sample:  
It was confirmed by  
§ Melting point  
§ FT-IR spectral analysis 
§ UV absorption maxima 
6.1.1. Melting point determination 
         Melting point is the temperature at which the pure liquid and solid exist in 
equilibrium. In practice, it is taken as equilibrium mixture at an external pressure of 1 
atmosphere; this is sometimes known as normal melting points. The Thiel’s tube 
method of melting point determination in liquid paraffin was used in the present 
study. Melting point was found to be in the range of 2270C which was in compliance 
with the official value. 
6.1.2. FTIR Spectra:  
         IR spectra of drug in KBr pellets at moderate scanning speed between 4000-
400 cm-1 was carried out using FTIR (Jasco FTIR 6100 type A). The peak values 
(Wave number) and the possibility of functional group shown in spectra which 
compare with standard value. The comparison of these results with Trimetazidine 
HCL chemical structure shows that the sample was pure Trimetazidine HCL.(Figure 
No.7). 
6.1.3. UV absorption maxima of Trimetazidine HCL: 
UV scanning was done for 10 mcg/ml drug solution from 200-400nm in 
phoushphate buffer 6.8 as a blank using double beams UV/VIS spectrophotometer. 
The wavelength maximum was found to be at 269 nm (Figure No.11).  
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6.2. Characterization of Drug: 
6.2.1  Physical description of Trimetazidine HCL: - 
Organoleptic properties: 
 Trimetazidine HCL is White or almost white crystalline  powder, odorless, slightly 
hygroscopic. 
 Solubility: very soluble in water, sparingly soluble in ethanol and practically 
insoluble in ether. 
Melting point: Its melting point found to be 227oC. 
6.3 Drug Excipients Compatibility study: 
        Compatibility of the drug with recipients was determined by FT-IR spectral 
analysis, this study was carried out to detect any changes on chemical constitution of 
the drug after combined it with the excipients. The samples were taken for FT-IR 
study. 
6.4 Preparation of buffers: 
6.4.1 Preparation of acidic buffers:- 
4 Preparation of 0.2 M hydrochloric acid: 
          HCL diluted with water to contain 7.292 gm of HCl in 1000ml.  
5 Preparation of 0.2 M sodium hydroxide solution- 
          Dissolve 8.0 g of sodium hydroxide pallets in 1000 ml of distilled water. 
6.4.2 Preparation of phosphate buffer:  
6 Preparation of 0.2 M potassium dihydrogen phosphate solution- 
Dissolve 27.213 g of potassium dihydrogen phosphate in 1000 ml of distilled            
water to get 0.2 M potassium dihydrogen phosphate. 
7 Preparation of 0.2 M sodium hydroxide solution- 
          Dissolve 8.0 g of sodium hydroxide pallets in 1000 ml of distilled water. 
8 Preparation of phosphate buffer pH 6.8 -  
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Place 50 ml of 0.2 M potassium dihydrogen phosphate and add 5.6 ml of 0.2 
M   of sodium hydroxide.  Dilute with distilled water to make up the volume 
up to 200ml. 
6.5 Preparation of Standard Calibration curve of Trimetazidine HCL- 
Weigh accurately 100mg of Trimetazidine Hcl WS into a 100-ml volumetric 
flask; Dissolve dilute to volume with phoushphate buffer pH.6.8 From the stock 
solution 10 ml was further diluted to 100 ml with purified water. Then from this 
solution aliquots of 0.3, 0.6, 0.9, 1.2, 1.5, 1.8, 1.4, 1.6, 1.8 and 2 ml were pipette out 
and made up to 10ml with phoushphate buffer pH 6.8 The Absorbance of above 
solution was measured at 269 nm by U.V.Spectrophotometer.  
        The spectrum peak point graph of absorbance of Trimetazidine HCL versus 
wave length was shown in Figure No.12. 
6.6 Evaluation of Powder and Grannuals: 
6.6.1 Angle of repose  
Flowability of different batch of granules was determined by calculating 
angle of repose by fixed height method. A funnel with 10 mm inner diameter of stem 
was fixed at a height of 2 cm. over the platform. About 10 gm of sample was slowly 
passed  along  the  wall  of  the  funnel  till  the  tip  of  the  pile  formed  and  touches  the  
steam of the funnel. A rough circle was drawn around the pile base and the radius of 
the powder cone was measured.  
Angle of repose was calculated from the average radius using the following 
formula.                                   
                                                       q = tan- (h/r) 
Where, q = Angle of repose, h = Height of the pile, r = Average radius of the powder 
cone. 
6.6.2. Bulk density and Tapped density 
        An accurately weighed quantity of the powder (W) was carefully poured into the 
graduated cylinder and the volume (vo) was measured then the graduated cylinder was 
closed with lid, set into the density determination apparatus (bulk density apparatus, 
electro  lab,  Mumbai).  The  density  apparatus  was  set  for  500  taps  and  after  that,  the  
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volume (Vf) was measured and continued operation till the two consecutive readings 
were equal. The bulk density, and tapped density were calculated using the following 
formulas. 
Bulk density   = W/Vo 
Tapped density  = W/Vf 
       Where,    Vo  = initial volume 
                 Vf   = final volume. 
6.6.3 Compressibility index: 
        The Compressibility index and Hausner ratio are measures of the propensity of a 
powder to be compressed. As such, they are measures of the relative importance of 
interparticulate interactions. In a free-flowing powder, such interactions are generally 
less significant, and the bulk and tapped densities will be closer in value. For poorer 
flowing materials, there are frequently greater interparticle interactions, and a greater 
difference between the bulk and tapped densities will be observed. These differences 
are reflected in the Compressibility Index and the Hausner Ratio.  
The compressibility index and Hausner ratio may be calculated using 
measured values for bulk density (  bulk) and tapped density (  tapped) as follows:  
                                                   tapped -  bulk 
   Compressibilty Index =       -----------------   X 100 
         tapped 
6.6.4 Hausner Ratio: 
It provides an indication of the degree of densification which could result 
from vibration of the feed hopper.  
                                 Tapped Density 
  Hausner Ratio = ----------------------- 
                                  Bulk density 
Lower Hausner ratio - Better flowability, 
 Higher Hausner ratio - Poor flowability  
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6.7 Formulation of Trimetazidine HCL Matrix Tablets: 
Each quantity mentioned will be taken in mgs, 
Total weight of the tablet = 180mg 
Each tablet contains      = 35mg of the Trimetazidine HCL 
Table No.4: Formulation of Trimetazidine HCL Matrix Tablets 
 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Trimetazidine 
Hcl 
35 35 35 35 35 35 35 35 35 
Metalose 35 52.5 70 ----- ----- ----- 35 35 35 
H.P.M.C.K15CR ----- ----- ----- 35 52.5 70 8.75 17.5 35 
Ethyl Cellulose 7 7 7 7 7 7 7 7 7 
Pregelatinised 
Starch 
27 27 27 27 27 27 27 27 27 
Microcrystaline 
Cellulose 
18 18 18 18 18 18 18 18 18 
Lactose 44 26.5 9 44 26.5 9 35.25 26.5 9 
P.V.P.K.30 7 7 7 7 7 7 7 7 7 
I.P.A. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Aerosil 1 1 1 1 1 1 1 1 1 
Talc 3 3 3 3 3 3 3 3 3 
Mg.Stearate 3 3 3 3 3 3 3 3 3 
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      Addition of Binders Solution 
 
 
                                                                      # 10 Screen 
 
                                                                         
                                                                          Drug in Hot air oven at 60°C                     
                                                                          
                                            
                                                                            # 22 Screen & Adding Lubricant 
                                                                         
 
                                                                                          
                                                                        
   
                                                       
 
                                                                
                                                                        
 
Figure No. 6:-Schematic representation of preparation of Matrix Tablet 
 
 
  
DRUG POLYMER 
MIXING IN A MOTAR AND PESTLE 
WET MASS IN MORTAR 
WET GRANULES 
WELL MIXING 
COMPRESSION 
MATRIX TABLET 
DRY GRANULES 
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6.8. COATING PROCEDURE 
           Weigh accurately H.P.M.C 6 CP and Ethyl Cellulose and mixed in half portion 
of I.P.A. Dissolve titaneous oxide, yellow iron oxide, talc in half portion of I.P.A. mix 
well half portion of metylene chloride was added in above solution.Dissolve PEG 
6000 in half portion of methylene chloride and added to above solution and stirred 
well.       
Table No. 6:-Coating Formula 
S. No. Ingredients Quantity 
1. H.P.M.C. 6 cp 5 mg 
2. Etyl Cellulose 0.5 mg 
3. Polyethylene Glycol 1 mg 
4. Titanium Dioxide 1 mg 
5. Yellow Iron Oxide 0.5 mg 
6. Talcum 1 mg 
7. I.P.A. 0.15 ml 
8 Methylene Chloride 0.2 ml 
 
6.9 Evaluation of Tablets: 
        All the prepared Sustained release tablets were evaluated for following official 
and unofficial parameters. 
v Weight Variation 
v  Thickness 
v Hardness Test 
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v Friability Test 
v Drug content 
v Dissolution Study 
6.9.1. Weight variation: 
        Twenty tablets were randomly selected from each batch and individually 
weighed. The average weight and standard deviation of 20 tablets was calculated. The 
batch passes the test for weight variation test if not more than two of the individual 
tablet weights deviate from the average weight by more than the percentage shown in 
Table no.10 and none deviate by more than twice the percentage shown. 
Table No.7:- Percentage deviation allowed under weight variation 
 
Percentage deviation allowed under weight variation test. 
Average weight of tablet (X mg) Percentage deviation 
X < 80 mg 
                
                      80 < X < 250 mg 
 
X > 250 mg 
10 
 
7.5 
 
5 
 
6.9.2. Thickness 
        Twenty tablets were randomly selected from each batch and there thickness and 
diameter was measured by using digital vernier caliper. 
6.9.3 Tablet Hardness 
        The crushing strength Kg/cm2 of prepared tablets was determined for 10 tablets 
of each batch by using Monsanto tablet hardness tester. The average hardness and 
standard deviation was determined. The results are shown in Table No.10 
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6.9.4. Friability: 
Method: 
       Twenty tablets were weighed and placed in the Electrolab friabilator and 
apparatus was rotated at 25 rpm for 4 minutes. After revolutions the tablets were 
dedusted and weighed again. The percentage friability was measured using the 
formula, 
% F = {1-(Wt/W)} ×100 
Where,  % F  = friability in percentage 
          W  = Initial weight of tablet 
          Wt   = weight of tablets after revolution 
The results are shown in Table 10. 
6.9.5 Assay Procedure: - 
Standard preparation: 
Transfer an accurately weighed quantity of about 40 mg of trimetazidine HCL to 
200 ml volumetric flask. Dissolve and dilute to volume with 0.1 N HCL and makeup the 
volume. 
Test preparation: 
Crush 20 tablets and weigh accurately 40 mg of powder equivalent to the 
trimetazidine HCL into 200 ml volumetric flask. Dissolve and dilute to the volume with 
0.1 N HCL and makeup the volume. Filter the test preparation through 0.45µ filter paper. 
Measure the absorbance of standard and test at 269 nm and calculate trimetazidine HCL 
by the following equation: 
                       Absorbance of sample       wt. of STD       200       avg. wt 
% ASSAY=      ----------------------------     x   -------------   x   ------   x   --------- x potency 
                       Absorbance of standard          200         test. Wt        L.C. 
 
The results are shown in Table No.10  
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6.9.6. In Vitro Dissolution Studies: 
        In Vitro dissolution study was carried out using USP II apparatus (paddle 
apparatus) in 900ml of phosphate buffer pH 6.8 for 8 hours. The temperature of the 
dissolution medium was kept at 37± 0.5oC and the paddle was set at 100 rpm. 10 ml 
of sample solution was withdrawn at specified interval of time. The absorbance of the 
withdrawn samples was measured at λmax 269nm using UV visible spectrophotometer. 
The concentration was determined from the standard curve of Trimetazidine HCL 
prepared in phosphate buffer pH 6.8 at λ max 269nm. Cumulative percentage of drug 
release was calculated using the equation obtained from a standard curve.  
6.9.7 Swelling Index 
        The swelling index of tablets was determined in phosphate buffer pH 6.8 at room 
temperature. The swollen weight of the tablets was determined at predefined time 
intervals. The swelling index was calculated by the following equation: 
 
Swelling index WU  =   (W1 – W0)   x 10 
                                            W0 
                   Where, Wt = Weight of tablet at time t. 
                     W0  = Initial weight of tablet 
6.9.8 Modeling of Dissolution Profiles   
        In vitro dissolution has been recognized as an important element in drug 
development under certain assessment of Bioequivalence. Several theories/kinetics 
models describe drug dissolution from immediate and modified release dosage forms. 
There are several models to represent the drug dissolution profiles where ft is a 
function of ‘t’ (time) related to the amount of drug dissolved form the pharmaceutical 
dosage system (Costa and Lobo,2001).Whenever a new solid dosage form is 
developed or produced, the drug release/dissolution from solid pharmaceutical dosage 
form is necessary to ensure that the drug dissolution occurs in an appropriate manner.                                       
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          The quantitative interpretation of the value obtained from the dissolution assay 
is facilitated by mathematical equation which translates the dissolution curve in 
function of some parameters related with the pharmaceutical dosage forms.   
In the present study, data of the in vitro release  were  fitted  to  different  
equations and kinetic models to explain the release kinetics of Trimetazidine HCL 
from the matrix tablets. The kinetic models used were a Zero order equation, Higuchi 
release. 
Drug release models: 
To describe the kinetics of the drug release from the matrix tablet batches, 
mathematical models such as zero-order, first order, Higuchi, Hixon-crowell models 
were used. The criterion for selecting the most appropriate model was chosen on the 
basis of the goodness-or fit test.  
The zero-order kinetic describes the systems in which the drug release rate is 
independent of its concentration. The first order kinetic describes the systems in 
which the drug release rate is concentration dependent. Higuchi described the release 
of drug from an insoluble matrix as square root of time dependent process.  
In case of the Higuchi square root model gives the drug release from a planer 
surface of an insoluble heterogeneous matrix by diffusion through the intragranular 
openings created by porosity of the matrix tablet.  
6.10 Stability Studies 
 Selected formulations were subjected to stability studies as per I.C.H. 
Guidelines. 
Following conditions were used for stability studies 
v 30°C/65 % RH analyzed till a period of 30 days 
v 40°C/75 % RH analyzed till a period of 30 days 
Following parameters  were check for stability studies 
Hardness, friability, drug content and in vitro release. 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
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RESULTS AND DISCUSSION 
7.1 IDENTIFICATION OF DRUG:- 
7.1.1 FTIR Spectra:  
IR spectra of drug in KBr pellets at moderate scanning speed between 4000-
400 cm-1 was carried out using FTIR (Jasco FTIR 6100 type A). The peak values 
(Wave number) and the possibility of functional group shown in spectra which 
compare with standard value.  
The comparison of these results with trimetazidine HCL chemical structure 
shows that the sample was pure Trimetazidine HCL. Figure No.7. 
7.1.2	UV	absorption	maxima	of	Trimetazidine	HCL:	
   UV scanning was done for 10 mcg/ml drug solution from 200-400nm in 0.1 
N HCL as a blank using double beams UV/VIS spectrophotometer.   The wavelength 
maximum was found to be at 269nm (Figure No. 11).  
7.2 Drug Excipients Compatibility study: 
                Compatibility of the drug with recipients was determined by FT-IR spectral 
analysis, this study was carried out to detect any changes on chemical constitution of 
the drug after combined it with the excipients. 
                The samples were taken for FT-IR study. (Figure No. - 8, 9, 10). 
 
 
 
 
 
 
 
	Department of  Pharmaceutics. AVPC 	Page		66
 
42
0.
03
49
1.
81
56
0.
30
59
6.
13
65
0.
18
67
6.
51
73
3.
91
76
2.
18
78
9.
09
84
6.
41
89
9.
21
95
4.
17
98
1.
28
10
09
.5
0
10
60
.3
21
08
9.
88
11
43
.1
2
12
08
.6
1
12
57
.6
612
80
.8
0
13
16
.7
8
13
33
.6
1
14
38
.8
314
66
.6
7
16
85
.3
3
20
81
.9
7
21
18
.6
8
28
13
.9
0
30
31
.9
2
31
59
.7
8
34
62
.0
4
 0.0
 0.1
 0.2
 0.3
 0.4
 0.5
 0.6
 0.7
 0.8
 0.9
 1.0
 1.1
 1.2
 1.3
A
bs
or
ba
nc
e
 500    1000   1500   2000   2500   3000   3500   4000  
Wavenumbers (cm-1)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No. 7:- IR Spectrum of Pure Drug (Trimetazidine HCL) 
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7.2.1 Drug Excipients Compatibility study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No. 8:- IR Spectrum of drug + HPMC K15 CR 
 
 
 
 
	Department of  Pharmaceutics. AVPC 	Page		68
 
 
 
 
 
 
 
                          
Figure No. 9:- IR Spectrum of Drug + Metalose 
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Figure No.10:-IR Spectrum of Drug + Ethyl cellulose 
   
 
  IR spectra studies revealed that the drug and polymers used were compatible. 
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7.3 Determination of λ max: 
 
 
 
 
Figure No.11:-Absorbance Maxima of Trimetazidine HCL 
   
7.4 Calibration Curve of Trimetazidine HCL 
 
Table No. 7:- Calibration curve of Trimetazidine HCL 
 
Concentration Absorbance at 269nm 
0 0 
3 0.049 
6 0.105 
9 0.162 
12 0.217 
15 0.266 
18 0.321 
21 0.386 
24 0.433 
27 0.495 
30 0.587 
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Figure No. 12:- Calibration Curve of Trimetazidine HCL 
 
7.5 Evaluation of Powders:- 
7.5.1 Preformulation Studies:- 
 
Table No.8:- Preformulation studies of pure drug and polymers 
 
Parameter 
Results 
Trimetazidine 
HCL 
HPMC-K-15 
CR 
Metalose Etyl Cellulose 
Angle of Repose 24 22 19 26 
Bulk Density 
(gm/cm3) 
0.46 0.31 0.35 0.60 
Tapped Density 
(gm/cm3) 
0.72 0.52 0.59 0.77 
Compressibility 
Index 
36.11 40.34 40.67 22.07 
Hauser’s Ratio 1.56 1.60 1.68 1.28 
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Table No. 9:- Preformulation studies of blend 
 
BATCH 
NO. 
BULK 
DENSITY 
(g/ml) 
TAPPED 
DENSITY 
(g/ml) 
COMPRSI 
BILITY 
(%) 
HOUSNER 
RATIO 
ANGLE OF 
REPOSE 
(°) 
F1 0.314 0.389 19.2 1.237624 250 
F2 0.368 0.426 13.6 1.157407 180 
F3 0.399 0.476 16.2 1.193317 200 
F4 0.354 0.416 17.51 0.86 29011’ 
F5 0.399 0.476 16.2 1.193317 20o12’ 
F6 0.421 0.512 17.7 1.215067 230 
F7 0.458 0.534 14.3 1.166861 200 
F8 0.316 0.409 29.43 0.77 31016’ 
F9 0.366 0.457 24.86 0.80 240 
 
            Preformulation study was done initially and results directed for the further 
course of formulation. Based on Preformulation studies different batches of 
Trimetazidine HCL (F1 to F9) were prepared using selected excipients. 
Powders were evaluated for tests Angle of repose, Bulk density, tapped 
density, compressibility index, Hausner ratio before being punched as tablets.  
7.5.2 Physico-Chemical Evaluation of Matrix Tablets:  
       The results of the thickness, Hardness, weight variation, drug content, friability, 
disintegration time of tablet are shown in Table No.10. 
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Table No. 10:- Results of Thickness, weight variation, Hardness, Friability and 
Drug content 
 
BATCH 
NO. 
WEIGHT 
VARIATION 
FRIABILITY 
(%) 
HARDNESS 
(kg/cm2) 
THICKNESS 
(mm) 
DRUG CONTENT 
(%) 
F1 ±4.0 0.12 4.5 3.9 96.20 
F2 ±2.0 0.19 5 4 97.26 
F3 ±3.0 0.39 5 4.1 98.93 
F4 ±2.55 0.14 5 4 97 
F5 ±2.0 0.24 5 3.9 99.89 
F6 ±3.44 0.11 5.5 3.8 98.53 
F7 ±2.0 0.43 4 4.1 97.11 
F8 ±5.66 0.16 5 3.9 97 
F9 ±5.22 0.18 5.5 3.8 96.00 
 
 7.5.3 In Vitro Dissolution Studies 
Table  No.11  shows the  data  for  in  vitro  release  of  Trimetazidine  HCL from 
matrix tablet of batches F1, F2, F3, F4, F5, F6, F7, F8 and F9 respectively. 
           As follows the dissolution profiles shows the comparative release profile of  
Trimetazidine HCL with different concentration  of  different polymer from batches 
F1, F2, F3, F4, F5, F6, F7, F8, F9 of matrix tablet.  
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Table No. 11:- Cumulative % Release of Drug of various Formulations 
Time 
(Hr) 
 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 40.5 41.1 42.31 38.25 45.04 36.83 33.78 37.47 34.61 
2 54.44 59.07 58.14 48.75 54.14 51.01 45.73 55.06 50.36 
4 80.51 84.25 81.38 81.18 78.1 73.38 67.16 77.81 68.95 
6 88.23 90.08 89.99 89.99 85.31 84.43 72.93 85.52 72.98 
8 91.19 92.86 92.95 92.95 86.84 89.96 85.02 87.75 80.77 
 
7.5.4 Percentage drug Release Profile of F1 to F9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No.13:- Graph of the Cum. % drug release versus Time (hrs) 
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7.5.4. % Swelling Index of Tablets of Batch F1 toF9 
 
Table No.12:- % Swelling Index of Tablets of Batch F1 toF9 
 
Batch 
TIME (HRS) 
0 1 2 3 4 5 6 
F1 0 32.23 41.38 54.32 63.78 74.12 81.2 
F2 0 49.25 61.54 72.90 82.37 92.54 100.22 
F3 0 29.09 39.45 51.32 61.12 71.97 80.35 
F4 0 39.21 51.92 63.76 72.52 84.2 96.56 
F5 0 45.65 53.35 64.32 75.45 80.09 94.58 
F6 0 56.73 66.76 77.72 82.26 94.60 101.25 
F7 0 39.06 47.96 55.32 65.34 76.09 87.11 
F8 0 25.87 36.54 47.86 57.98 69.96 72.44 
F9 0 26.76 40.98 49.54 59.06 69.78 75.99 
 
 
 
Figure No. 14:- Comparison of % swelling index of various formulations 
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7.5.5 Kinetic assessment of Extended release Matrix tablet containing 
Trimetazidine HCL- 
 
Huguchi Modeling - 
 
Table No. 13:- Huguchi Modeling  
 
BATCHES 
R2 VALUE 
(ZERO ORDER) 
R2 VALUE 
(HUGUCHI) 
F1 0.809 0.971 
F2 0.787 0.961 
F3 o.798 0.969 
F4 0.802 0.975 
F5 0.768 0.955 
F6 0.851 0.988 
F7 0.865 0.991 
F8 0.802 0.968 
F9 0.807 0.973 
 
         
 
Figure No. 15:- Huguchi Modeling 
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Figure No. 16:- Zero order Modeling 
 
7.6 Stability Study of Optimized Formulation: -  
      As per I.C.H. Guidelines 
Table No. 14: Stability studies of formulation F-9 stored at 30°C/65 % RH 
Time (hr) 
Cumulative % Drug Release 
Initial After 30 Days 
0 0 0 
1 34.61 34.01 
2 50.36 50.98 
4 68.95 67.33 
6 72.98 71.61 
8 80.77 80.11 
Hardness 5.5 5.5 
Friability 0.18 0.17 
Drug 
content 
96 95.92 
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Table No-15:- Stability studies of formulation F-9 stored at 40°C/75 % RH 
Time (hr) 
Cumulative % Drug Release 
Initial After 30 Days 
0 0 0 
1 34.61 33.53 
2 50.36 50.12 
4 68.95 66.65 
6 72.98 72.53 
8 80.77 79.78 
Hardness 5.5 5.5 
Friability 0.18 0.18 
Drug 
content 
96 94.99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND 
CONCLUSION 
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SUMMARY AND CONCLUSION 
 Oral route of drug administration is oldest and safest mode of drug 
administration.  It  posses  several  advantages.  It  provides  accurate  dosing  without  
assistantship of administration. In conventional oral drug delivery system, there is 
little or no control over release of drug, and effective concentration at the target site 
can be achieved by administration of grossly excessive dosage form. Sustained 
release technology is relatively new field and as a consequence, research in the field 
has been extremely fertile and has produced many discoveries. With many drugs, the 
basic goal is to achieve a steady state blood level that is therapeutically effective and 
non-toxic  for  an  extended  period  of  time.  The  design  of  proper  dosage  form  is  an  
important element to accomplish this goal. 
Trimetazidine HCL is Vasodilator with half life of 6 hours and requires 
multiple daily doses to maintain adequate plasma concentrations. So it is selected to 
prepare  an  extended  release  Matrix  tablet.  The  objective  of  this  present  study  is  to  
develop an extended release Matrix tablet of Trimetazidine HCL which releases the 
drug in an extended manner over a period of 8 hours, by using different polymers and 
study on polymer concentration effect on release pattern. 
        The present study was undertaken with an aim to formulate develop and evaluate 
Trimetazidine HCL extended release matrix tablets using different polymers as 
release retarding agent. 
        Preformulation  study  was  done  initially  and  results  directed  for  the  further  
course of formulation. Based on Preformulation studies different batches of 
Trimetazidine HCL were prepared using selected excipients. Powders were evaluated 
for tests Angle of repose, Bulk density, tapped density, compressibility index, and 
Hausner ratio before being punched as tablets.  
         IR spectra studies revealed that the drug and polymers used were compatible. 
        Various formulations of sustained release matrix tablets of Trimetazidine HCL 
were developed using various polymers viz, HPMC K-15CR, Hypermellose, Ethyl 
Cellulose in different proportions and combinations by Wet Granulation technique. 
	Department of  Pharmaceutics. AVPC 	Page		80
 
The tablets were evaluated for physical characterization, in vitro swelling behavior, in 
vitro release study and stability studies. 
        Observations of all formulations for physical characterization had shown that, all 
of them comply with the specifications of official pharmacopoeias and/or standard 
references. 
        Results of in vitro release profile indicated that formulation F9 was the most 
promising formulation as the extent of drug release from this formulation was high as 
compared to other formulations. Results of in-vitro swelling study indicate that the 
formulation F9 was having considerable swelling index. 
        Stability study was conducted on tablets of Batch F9 stored at 300C (Room 
Temperature) and 400C for one month. Tablets were evaluated for hardness, friability, 
in-vitro release profile and drug content. After one month no significant changes were 
observed in any of the studied parameters during the study period, thus it could be 
concluded that formulation was stable. It was concluded that the tablets of batch F9 
had considerable swelling behaviors and in vitro drug release. Percentage drug release 
in 8 hr is 80.77.  It was observed that tablets of batch F9 followed the Huguchi release 
profiles.  
        From the above results and discussion it is concluded that formulation of 
Extended release matrix tablet of Trimetazidine HCL containing HPMC K-15 
(19.44%) and Hypermellose (19.44%), Ethyl cellulose (19.44%) batch F9 can be 
taken as an ideal or optimized formulation Extended release matrix tablet for 8 hour 
release as it fulfills the requirements for extended release matrix tablet.  
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